




# Management of surgical diseases of thyroid gland indications of the United Italian Society of Endocrine Surgery (SIUEC)

P. Del Rio<sup>1</sup> · A. Polistena<sup>2</sup> · M. G. Chiofalo<sup>3</sup> · L. De Pasquale<sup>4</sup> · G. Dionigi<sup>5,6</sup> · G. Docimo<sup>7</sup> · G. Graceffa<sup>8</sup> · M. Iacobone<sup>9</sup> · Fabio Medas<sup>10</sup>  · A. Pezzolla<sup>11</sup> · S. Sorrenti<sup>12</sup> · S. Spiezia<sup>13</sup> · P. G. Calò<sup>10</sup>

Received: 30 December 2022 / Accepted: 23 April 2023 / Published online: 18 May 2023  
© The Author(s) 2023

## Abstract

A task force of the United Italian society of Endocrine Surgery (SIUEC) was commissioned to review the position statement on diagnostic, therapeutic and health-care management protocol in thyroid surgery published in 2016, at the light of new technologies, recent oncological concepts, and tailored approaches. The objective of this publication was to support surgeons with modern rational protocols of treatment that can be shared by health-care professionals, taking into account important clinical, healthcare and therapeutic aspects, as well as potential sequelae and complications. The task force consists of 13 members of the SIUEC highly trained and experienced in thyroid surgery. The main topics concern clinical evaluation and preoperative workup, patient preparation for surgery, surgical treatment, non-surgical options, postoperative management, prevention and management of major complications, outpatient care and follow-up.

**Keywords** Italian Society of Endocrine Surgery · Recommendations · Surgical diseases of thyroid gland · Thyroidectomy

## Introduction

The United Italian Society of Endocrine Surgery (SIUEC) was established in Bari in 2017 from the union of two pre-existing societies (the Italian Society of Endocrine Surgery, SIEC and the Italian Association of Endocrine Surgery Units, U.E.C. CLUB). Following the long history and activities of the two founder societies, SIUEC promoted in the

last 5-year several conferences, congresses, scientific publications and professional training activities. There is a specific need to define and promote among the entire endocrine surgical community in Italy updated recommendations for the diagnosis and management of surgical thyroid diseases, according to international protocols.

At the light of new technologies, recent oncological concepts, tailored approaches and based on the previous

✉ Fabio Medas  
fabiomedas@unica.it

<sup>1</sup> Unit of General Surgery, Department of Medicine and Surgery, University of Parma, Parma, Italy  
<sup>2</sup> Department of Surgery Pietro Valdoni, University of Rome Sapienza, Rome, Italy  
<sup>3</sup> Department Head and Neck, Thyroid Surgery Unit, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Naples, Italy  
<sup>4</sup> Thyroid and Parathyroid Service, Otolaryngology Unit, ASST Santi Paolo e Carlo, Department of Health Sciences, University of Milan, Milan, Italy  
<sup>5</sup> Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy  
<sup>6</sup> Division of Surgery, Istituto Auxologico Italiano Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy

<sup>7</sup> Division of Thyroid Surgery, University of Campania “L. Vanvitelli”, Naples, Italy

<sup>8</sup> Department of Surgical Oncological and Oral Sciences, University of Palermo, Palermo, Italy

<sup>9</sup> Endocrine Surgery Unit, Department of Surgery, Oncology and Gastroenterology, Padova University Hospital, Padova, Italy

<sup>10</sup> Department of Surgical Sciences, University of Cagliari, Cagliari, Italy

<sup>11</sup> Division of Videolaparoscopic Surgery, Department of Emergency and Organ Transplantation, University of Bari “A. Moro”, Bari, Italy

<sup>12</sup> Department of Surgery, “Sapienza” University of Rome, Rome, Italy

<sup>13</sup> Department of Endocrine and Ultrasound-guided Surgery, Ospedale del Mare, Naples, Italy

experience of the position statement on diagnostic, therapeutic and health-care management protocol in thyroid surgery published in 2016 by the U.E.C. CLUB [1], an updated revision of the previous protocol was drafted by a SIUEC experts' commission to provide clear clinical indications for endocrine surgeons in Italy. The objective of this publication is to support surgeons with modern rational protocols of treatment that can be shared by health-care professionals, taking into account important clinical, healthcare and therapeutic aspects, as well as potential sequelae and complications.

Comprehensive recommendations in the different clinical scenarios were provided.

However, it is not within the scope of the authors nor of the SIUEC to influence in any way the physician–patient relationship, which is based on trust and clinical judgment in each individual case.

Topics:

- SIUEC accreditation system for thyroid centers
- Clinical evaluation and preoperative workup;
- Hospital admission and waiting time;
- Therapeutic pathway:
  - patient preparation for surgery,
  - surgical and thermoablative treatment,
  - postoperative management,
  - prevention and management of major complications
- Hospital discharge and patient information;
- Outpatient care and follow-up.

### SIUEC accreditation system for thyroid centers

SIUEC has set up an accreditation system to verify the possession by each endocrine surgical unit of qualitative and quantitative requirements, and to stratify the centres regarding the level of competence. The following conditions are needed to obtain accreditation as thyroid centre: at least two surgeons devoted to thyroid surgery with appropriate training and number of thyroidectomies performed, routine application of international guidelines, at least 50 thyroidectomies performed each year, 24-h anaesthesiologic ward, accessibility to intensive care unit and cardiological intensive care unit, pathologist with experience in thyroid diseases, imaging (US, CT) available on a 24-h basis, presence of services of endocrinology, otolaryngology, nuclear medicine, vascular surgery in the same hospital or in a local or regional network. The centres with these requirements are defined as thyroid referral centres; in addition, centres performing  $\geq 500$  thyroidectomies per year are accredited as national thyroid referral centres.

## Clinical evaluation and pre-operative work up

A careful endocrinological evaluation, in terms of history, physical examination, laboratory and imaging, improves the surgical approach to thyroid disease facilitating the best tailored treatment. A multidisciplinary team (MDT) is advocate for thyroid disease management which includes specialists in: endocrine surgery, endocrinology, head and neck radiotherapy, oncology, nuclear medicine. MTD is required to provide individualized and optimal multimodality treatment for the initial evaluation and for further follow-up and treatments.

Medical history should be stored for previous malignancy, neck or whole-body irradiation for bone marrow transplantation, exposure to ionizing radiation during childhood, familial syndromes that include thyroid cancer (such as MEN 2, Werner Syndrome, Cowden Syndrome, familial polyposis, Carney complex, etc), clinical records as dysphonia, dysphagia, overgrowth of normal thyroid tissue. Physical examination of the neck includes an accurate inspection of the neck for any scars, mass or nodular enlargement; a complete palpation of thyroid gland between the cricoid cartilage and the suprasternal notch and palpation of the thyroid gland, the adjacent lymphatic chains, any present masses.

## Laboratory studies

### First-tier assessments

TSH serum level should be obtained for the first endocrinological evaluation [1–3] In case of a suppressed TSH (hyperthyroidism) FT3, FT4 and anti -TPO -TG -TSH receptor antibodies are required,

In the instance of an elevated TSH (hypothyroidism) only antibodies anti TPO and anti TG are recommended.

- Serum calcium and phosphorus should be checked routinely.

### Second-tier assessments

Calcitonin (CT) is a reliable serum marker of medullary thyroid carcinoma (MCT) largely used for diagnosis and follow-up. Clearly (over cut-off) high serum values found in patients affected by undiagnosed thyroid nodules prevent the need of FNA for cytological assessment, often inconclusive or indeterminate, or for intralesional thyroid CT dosage. However, CT dosage remains essential in case of suspicious lymph node metastases, both in preoperative assessment and in case of suspected recurrent disease. The CT measurement

provides an earlier diagnosis and allows the familial screening with the subsequent improvement of surgical outcome and patients survival. Borderline values may require a further evaluation to avoid false positive results, due to interference of drugs (as pump inhibitors) or co-morbidity. In doubt cases, as well as for screening RET gene carriers and to differentiate between C-cell hyperplasia and medullary thyroid cancer [1, 3, 4] calcium gluconate stimulation test may be performed.

The routine measurement of calcitonin is still debated in literature because of the rare occurrence of CMT in front of the overall thyroid malignancies (5–10%) and in front moreover of the overall thyroid disorders, conditioning a relatively low CMT predictivity. It is actually recommended to measure the level of CT prior to thyroidectomy.

- CEA dosage is required in all patients with elevated CT, representing an unfavorable prognostic factor. Conversely, CT dosage is mandatory in patients presenting incidental high serum CEA.
- Serum calcium is useful for the screening of an incidental primary hyperparathyroidism [5].
- Serum phosphate and parathyroid hormone (PTH) In case of hypercalcemia [5].
- Anti-TPO (anti-thyroid peroxidase) and anti-Tg(anti-thyroglobulin) antibodies in case of suspected autoimmune disease [1, 4–6].
- TSH-receptor antibody (TRab) in case of suspected Grave's Disease [1, 4–6].

## Instrumental studies

### First-tier assessments

- Thyroid ultrasound (US)with colour flow Doppler scanning represents an essential test in all patients with a clinical suspicion of thyroid nodule and/or nodular goitre, in all cases of incidental radiological finding of thyroid nodular disease (CT or MRI of the neck, thyroïdal uptake on 18FDG- PET scan, etc.). Ultrasonography allows an accurate morphological evaluation of the thyroid and adjacent regional lymph nodes aimed at the acquisition of specific information regarding [1, 3, 5–7]:
  - location, size (possibly total gland volume) and structure of the lobes;
  - the presence, number, size and structure (solid, cystic, mixed) of the thyroid nodules;
  - vascular pattern of the nodule on colour Doppler;

- status of the contralateral lobe in case of unilateral disease;
- nodular features indicative of malignancy (hypoechoogenicity, micro-calcifications, absence of halo, irregular margins, chaotic intranodular vascularity, round shape);
- condition of the trachea (midline, displaced, compressed);
- status of regional lymph nodes (reactive or suspicious).

The American College of Radiology Thyroid Imaging Reporting and Data Systems (TIRADS) is a 5-point classification to determine the risk of cancer in thyroid nodules based on ultrasound characteristics. This classification is actually largely used to an accurate study of patients affected by thyroid nodules [6].

### Second-tier assessments

Second-tier assessments are aimed at further diagnostic evaluation and at defining the therapeutic strategy, particularly in case of minimally invasive approaches and re-intervention:

- *Fine-needle aspiration cytology (FNAC)* is the most accurate and cost-effective method for evaluating thyroid nodules. Ultrasound guidance, cyto-assisted procedure (cytologist present), significantly reduces the number of non- diagnostic results and false negatives, especially in the case of nodules with a high likelihood of non-diagnostic cytology (> 25–50% cystic component) and/or difficult to palpate or posteriorly located nodules.

FNAC is indicated in all clinically or sonographically suspicious nodules with a diameter  $\geq 1$  cm. It is not recommended as a routine procedure for subcentimetric nodules; however, for nodules < 1 cm, FNAC is recommended in the following situations:

- family history of thyroid cancer,
- the presence of suspicious cervical lymphadenopathy,
- prior radiation therapy to the head, neck and/or mediastinum,
- exposure to ionizing radiation during childhood or adolescence,
- nodule with suspicious sonographic features (hypoechoogenicity, microcalcifications, marked vascularity).

**Table 1** The Italian thyroid cytology classification system (SIAPEC-IAP 2014) compared with the revised Bethesda reporting system (2017). The risk of malignancy of the revised Bethesda classification are reported considering the NIFTP as cancer

2014 Italian SIAPEC-IAP reporting system	Risk of malignancy (%)	2017 revised Bethesda reporting system for thyroid cytology
TIR 1 non-diagnostic TIR 1C non-diagnostic—cystic	Low	I. Non-diagnostic
TIR 2 benign	< 3	II. Benign
TIR 3A low-risk indeterminate lesion	10–30	III. Atypia of undetermined significance (AUS)/follicular lesion of undetermined significance (FLUS)
TIR 3B High-risk indeterminate lesion (oncocyctic lesions included)	25–40	IV. Follicular neoplasm or suspicious for a follicular neoplasm (FN/SFN) (oncocyctic lesion FNHCT/SFNHCT included)
TIR 4 suspicious of malignancy	50–75	V. Suspicious of malignancy
TIR 5 malignant	97–99	VI. Malignant

The cytology report should be descriptive, but also end with the assignment of the patient to a clearly defined and identifiable diagnostic category [1, 4–7].

After the publication of the Italian Societies of Endocrinology and the SIAPEC-IAP, in 2010–2014 [8, 9], the cytological classification is largely adopted (Table 1) and the retrospective cross-sectional survey, published in 2019, reports that the new SIAPEC-IAC criteria significantly increased the proportion of the overall TIR3 diagnosis. The division of TIR3 nodules into two subgroups (A and B) allowed a better evaluation of the oncologic risk and a better selection of patients for surgery [10]. In addition, if the cytological finding is uncertain, it is recommended to check the FNAC for BRAF V600E mutation.

- *Contrast-enhanced ultrasound (CEUS)* represents a non-invasive technique for the differential diagnosis of thyroid nodules. However, due to the operator-dependent evaluation, CEUS has rather variable sensitivity (68–100%) and specificity (67–94%) [11].
- *Thyroid 99Tc-Perteneccate scintigraphy* Indications for this investigation are limited to [12]:
  - subclinical or overt hyperthyroidism,
  - recurrent goiter,
  - suspicion of forgotten or ectopic goiter.

Radioactive iodine uptake test is reserved to patient proposed to 131- I treatment

- *Elastography* measures the degree of distortion of a tissue subjected to an external force and can therefore determine the elasticity of the tissue being examined. Malignant lesions often associate with changes in tissue mechanical properties; therefore, this technique may help refine the diagnosis of the lesion being examined. How-

ever, the applicability of elastography in clinical practice is limited by the variable sensitivity (54–69%) and specificity (60–96%) described in different reports [13].

- *Core needle biopsy (CNB)* Tissue biopsy is obtained by a cutting needle, usually equipped with a retractable spring-loaded mechanism (18–21 G Trucut needle). This method is carried out only under ultrasound guidance. The sampling of tissue that includes the periphery of the nodule and the surrounding thyroid parenchyma allows examining the architectural characteristics of the thyroid tissue, allowing a microhistological diagnosis. Recently, indications to CNB have been extended to nodules with inadequate (Tir 1) or indeterminate (Tir 3) cytology [12].
- *CT/MRI* These alternative imaging modalities may be useful in the assessment of large, rapidly growing, or retrosternal or invasive tumors to assess the involvement of extrathyroidal tissues [1, 4, 12, 14].
- *18F-FDG PET-CT* At present, 18F-FDG PET-CT cannot be considered a routine investigation [1, 4, 14] The procedure is indicated in re-staging patients presenting in the follow-up persistent or recurrent elevated serum thyroglobulin (DTC) or CMT calcitonin (CMT) levels due to local tumor persistence and/or distant progression/relapse. It is indicated also in preoperative staging of CMT, with diagnostic and prognostic value in association with DOPA-PET

This technique, to-day widely used by oncologists for the cancer staging, may incidentally reveal areas of increased uptake inside the thyroid gland, called “incidentalomas”, which, in 25 % of cases, turn out to be cancer.

-\* *DOPA PET-CT* is reserved to preoperative total body staging of CMT and to imaging the adrenal glands in hereditary MEN syndromes.

- *Laryngeal fibroscopy* Preoperative laryngoscopy is recommended in candidates to thyroidectomy to assess the

morphological and functional integrity of the vocal folds. US evaluation of VC motility may be an alternative. Mandatory indications are indicated as follows [1]:

- Patients complaining dysphonia
- Re-intervention (to exclude potential pre-existing injury of laryngeal nerves)
- Symptomatic large or substernal goiter
- Locally invasive thyroid cancer

## Hospital admission and waiting time

### Priority for hospital admission

In accordance with the Italian National Plan for the governing of waiting lists 2019–2021 [15], four priority classes for hospital admission are recognized for each pathology.

- Class A: hospitalization within thirty days for clinical cases that can potentially worsen rapidly to the point of becoming emerging or, in any case, seriously damaging the prognosis (All tumors, except Differentiated Thyroid Carcinoma < 1 cm limited to the gland without lymph node involvement, patients with severe thyrotoxicosis, patients with large goiter affecting significant stenosis of the airways)
- Class B: hospitalization within 60 days for clinical cases that present intense pain, or severe disability, and do not show a tendency to aggravate it nor can, due to the wait, seriously harm the prognosis (Differentiated Thyroid Carcinoma < 1 cm limited to the gland without lymph node involvement, Tir 3B and large Tir 3A nodules, hyperfunctioning disease without thyrotoxicosis, but with labile hormonal control with medical therapy)
- Class C: hospitalization within 180 days for clinical cases that present minimal pain, dysfunction or disability, and do not show a tendency to worsen nor can for the wait receive serious damage to the prognosis. (Hyperfunctioning goiter or Plummer adenoma with good hormonal control with medical therapy, goiter or cytologically benign nodules with a tendency to grow)
- Class D: hospitalization without maximum waiting time defined for clinical cases that do not cause any pain, dysfunction, or disability. However, these cases must be carried out at least within 12 months. (Large goiter stable with minimal growth at follow-up, goiters or Plummer

with subclinical hyperthyroidism without the need of medical therapy)

### Pre-admission workup (or upon admission)

- Blood chemistry, complete blood count and coagulation tests for surgery;
- ECG;
- Chest X-ray (where indicated, depending on patient's age and comorbidities);
- Anesthesiology consultation;
- Vocal cord assessment.

### Recommendations for patients

- Patients should continue their current thyroid medications (methimazole, propylthiouracil, thyroxine, beta-blockers taken on a regular basis) until the day prior to surgery, unless otherwise indicated due to medical or anesthesiological reasons;
- Patients in treatment with vitamin K antagonist anticoagulants should discontinue therapy 3–5 days before surgery and should replace it with LMWH (last administration 24 h before surgery) [16];
- Patients in treatment with Non-vitamin K antagonist oral anticoagulants should discontinue therapy from 24 to 36 h before surgery to 1–2 days after surgery, without bridging them with LMWH [16–18];
- Patients should discontinue treatment with Clopidogrel or Ticagrelor 5 days before surgery, with Prasugrel 7 days before surgery, while Aspirin treatment does not need pre-operative cessation [16].

### Admission

On the same day of surgery, unless otherwise indicated or required, but ensuring an appropriate timing for a detailed doctor-patient discussion about the surgical procedure and its risks, so that the patient can express his consent to the surgery in written documentation.

## Therapeutic pathway

### Patient preparation for surgery

- Antibiotics: antibiotic prophylaxis is not indicated in thyroidectomy [19, 20] except for particular cases, such as: severe diabetes, cardiac valvular disease, immune deficiency (hemodialysis or transplanted patients).

- Antithrombotic prophylaxis: international guidelines [19, 21] do not make specific recommendations regarding thyroid or neck surgery.
- Blood units: autologous pre-deposit blood donation or preparation of blood units for thyroidectomy is not justified.
- Position on the operating table (joint responsibility of the surgeon and anesthesiologist): patient in the supine position with a small wedge beneath the shoulders, at the scapular level, such to allow a mild hyperextension of the neck; with the neck in hyperextension, although mild, arms should be adducted and secured next to the patient's body in order to avoid rare, but severe and sometimes irreversible, brachial plexus paralyses due to stretch injury [22]; elbows should be adequately padded to avoid ulnar nerve paralysis secondary to compression; eye protection to avoid corneal ulceration and ocular trauma. When using intraoperative neuromonitoring, the endotracheal tube must be placed in a perfect position so that the surface electrodes adhere correctly to the vocal cords. Collaboration with the anesthetist is important.

### Informed consent

Patients should be adequately informed by the surgeon of the indications for surgery, possible alternative treatments, advantages expected from surgery, general and specific complications, rehabilitation therapy—if needed, and the clinical consequences of potential permanent postoperative injuries.

The information provided should be clearly explained, complete and prompt. After providing the most complete information, the physician will seek the patient's consent to perform surgery, taking into full consideration any expression of dissent, even on individual aspects of the procedure or its potential consequences.

Transmission of information and the informed consent should preliminarily take place during the first visit and be renewed upon admission, before surgery, especially if enough time has passed such that the initial conditions may have changed. In fact, the patient must be given the opportunity to discuss in depth with his/her physician (or other trusted person) the information received and, if desired, to get information on the health facility where he or she will be treated and/or on the team that will perform the surgery.

Given the peculiarity of the therapeutic intervention (partial or total removal of the thyroid gland) and its potential consequences on the physical integrity of the subject [1] it is necessary that written documentation of the informed and conscious consent be retained, and that the informed consent process be documented in a specific chart note.

To this end, SIUEC is preparing a standardized consent form that will be made available on the website (<https://siuec.it/>).

### Surgical treatment

Of all the procedures that have been proposed for thyroid surgery, the following can be considered to be in current use [3, 19, 23–27]:

- Lobectomy plus isthmectomy
- Total thyroidectomy (considered as synonym for near-total thyroidectomy, as the presence of remnants, although minimal, is pretty much constant, without affecting the radicality of the intervention)
- Completion thyroidectomy after lobectomy

Beside classical surgical interventions, two new approaches must be introduced for the management of benign thyroid nodule and thyroid cancer in selected high-risk patients and of low-risk microcarcinoma:

- Percutaneous ablation (see appropriate section)
- Active surveillance (see appropriate section)

The surgical report must be accurate and provide a description of the thyroid gland and the macroscopic characteristics of the most relevant nodules, dimensions, inflammatory tissue, air way compression.

The surgeon must also report on the identification and preservation of the external branch of the superior laryngeal nerve, the identification of the inferior laryngeal nerves, the anatomical variations, mentioning dissection difficulties, if any [28–30]. The surgical report must highlight the side and number of parathyroid glands identified. A decision to leave macroscopic thyroid tissue in situ should be substantiated as the location and size. If neuromonitoring is used during surgery, the technique performed (intermittent or continuous) must be reported as the signal coded as per protocol. In case of Loss of signal we can choose the two-stage thyroidectomy; this should be accurately reported in the report. The use of the energy devices must also be reported in the report. (for neuromonitoring see appropriate section)

### Minimally invasive techniques

In the last few years, several techniques have been developed for minimally invasive thyroidectomy [31, 32]. Minimally invasive approaches for thyroidectomy can be classified into techniques with and without the use of endoscope.

The minimal incision thyroidectomy (MIT) differs from conventional thyroidectomy by a shorter skin incision and involve the use of optical aids (magnifying glasses 2.5 × 3.5) [31]. Techniques that involve the use of an endoscope can be divided into pure endoscopic techniques and video assisted techniques. An important limitation of endoscopic techniques is the difficulty of purely endoscopic dissection,

**Table 2** Indication and contraindication to MIVAT

Indications	Contraindications	Relative contraindications
Thyroid nodules < 35 mm	Prior neck surgery	Prior neck irradiation
Thyroid volume < 30 ml	Locally advanced thyroid carcinoma	Thyroiditis or Graves disease
Low and intermediate risk papillary thyroid carcinoma	Preoperative evidence of lymphnode metastases	
Patients with RET gene mutation		

**Table 3** Indications and contraindications to robotic thyroidectomy

Indications	Contraindications	Relative contraindications
Benign disease:nodule < 5 cm	Previous thyroid or breast surgery	Arthrosis or previous surgery of the shoulder joint
Indeterminate nodules	Previous head and neck irradiation	Thyroiditis or Graves’ disease
Small differentiated thyroid carcinoma	Electronic medical devices (pacemakers,defibrillators in the pectoral region)	BMI > 30
		Distance from the axilla to the sternal notch > 15 cm

especially when using accesses that are completely different from those used in conventional surgery (axillary, breast, chest access), which limited their application to the experiences reported by the authors who have proposed such approaches [31, 33]. Minimally invasive videoassisted thyroidectomy (MIVAT) is a totally gasless technique that involves a 1.5–2.0 cm central horizontal incision, use of a 5 mm 30° endoscope and dedicated dissection tools [34–36].

This technique was born more than 20 years ago, has large consensus and is safe and reproducible, with similar complication as compared to conventional surgery and significant advantages in terms of postoperative pain and discomfort, as well as of the aesthetic improved outcome and was supported over time by the use of increasingly performing laparoscopic columns in defining and magnifying the operating field [37–41].

Its wide diffusion allowed to collect data on its safety in the treatment of DTC with low–intermediate risk. Indications and contraindications to MIVAT are reported in Table 2 [34, 35, 37, 38, 42–44]. Among the minimally invasive methods, the Trans-Oral Endoscopic Thyroidectomy Vestibular Approach (TOETVA) although largely reported in clinical studies, is still in a validation phase and requires a further confirmation on a larger clinical experience for a correct comparison not only of feasibility but also of complication rates [45, 46].

**Robotic thyroidectomy**

The use of robotic technology has improved in the last years and allows, in the head and neck area, several indirect approaches for thyroidectomy: gasless transaxillary (the

most used) [32, 47], transoral [48] and retroauricular [49] and axillo-breast approach [50].

Indication and contraindications to robotic thyroidectomy [47, 51] are reported in Table 3.

The use of transaxillary robotic approach to thyroidectomy is a feasible and safe option in selected patients who refuse incisions in the cervical region [32, 52, 53].

**Intraoperative nerve monitoring (IONM)**

Injury to the inferior laryngeal nerve is one of the most feared complications following thyroidectomy, and medical litigation is becoming more frequent [19, 54–59].

In addition, it is well known that the anatomical integrity of nerves and thus not all nerve injuries are recognized intraoperatively [60–62].

Several techniques have been proposed for intraoperative monitoring of the recurrent laryngeal nerve (IONM). However, the most widely used and standardized method is the use of endotracheal tube surface electrodes placed in contact with the mucosa of the vocal cords [62, 63] Use of the IONM should also be indicated to identify the external branch of the superior laryngeal nerve (EBSN) [30].

The use of IONM during thyroidectomy (conventional-mini-invasive) may be associated with a significant reduction in the risk of bilateral vocal cord palsy if loss of signal to the inferior laryngeal nerve or vagus nerve is detected after the first lobectomy during total thyroidectomy [64–66].

It is of utmost importance to perform neuromonitoring according to the steps indicated in Table 4 [63]. More promising results are expected from continuous intraoperative

**Table 4** IONM Standards steps.

L1: vocal cord examination with preoperative laryngoscopy
V1: stimulation of the ipsilateral vagus before RLN dissection
R1: stimulation of the RLN at the first point where it is found in the tracheoesophageal groove
S1: stimulation of the EBSLN with the probe after it has been detected
S2: stimulation of the EBSLN proximal to the point where superior thyroid vessels are separated, following separation of the vessels and successful bleeding control
R2: stimulation of the RLN at its most proximal point after the dissection is complete
V2: vagus stimulation after bleeding control is complete at the surgical field
L2: vocal cord examination with postoperative laryngoscopy

nerve monitoring (C-IONM), which allows real-time assessment of inferior laryngeal nerve function during surgical manoeuvres and thus could prevent intraoperative injury [67].

### Surgical treatment of hyperthyroidism

The most common causes include Graves' disease (GD), toxic multinodular goiter (TMNG), and toxic adenoma (TA). Treatment strategy in hyperthyroidism firstly requires recovery of euthyroidism by antithyroid therapy; however, patients that not reach an euthyroidism state, even after antithyroid therapy, can be safely operated. Beta-adrenergic blockade is recommended in all patients with symptomatic thyrotoxicosis, especially in elderly patients. No particular treatment modality, among RAI, antithyroid medications or surgery, has demonstrated superiority over the others. Treatment modalities, pro-cons and side-effects need to be shared and discussed with the patient [68].

RAI is the most commonly used definitive treatment option for GD. Surgery offers a definitive treatment too and it is proposed as a first line treatment, primarily for patients with severe ophthalmopathy or goiter. Relapse rate is highest among patients receiving anti-thyroid drugs (approximately 40%), followed by RAI (21%), whereas surgery is associated to the lowest rate (<5%) [69].

Total thyroidectomy is more effective than subtotal thyroidectomy at preventing recurrent hyperthyroidism in Graves' disease and it is therefore recommended as the option of choice. Furthermore the type of surgery does not affect regression of Graves' ophthalmopathy [70]. If surgery is performed for all of the above conditions of hyperthyroidism, a preoperative treatment with methimazole must be administered; potassium iodide may be given in the immediate preoperative period in GD. Antithyroid drugs should be stopped at the time of thyroidectomy and beta-adrenergic blockers should be maintained and weaned following surgery.

Surgical options include:

- Isolated toxic adenoma (TA): an ipsilateral thyroid lobectomy, or isthmectomy if the adenoma is in the

thyroid isthmus, should be performed for isolated TAs. Large nodules ( $\geq 3$  cm), compressive symptoms and contraindication to RAI are specific indications to surgical treatment.

- Toxic multinodular goiter (TMG): near-total or total thyroidectomy are recommended.
- Flajani–Basedow–Graves' disease (FBGD): near-total or total thyroidectomy are the procedures of choice (specific indication are the above mentioned for TA plus ineffectiveness or recurrence after thyrostatic treatment, young age and severe and ophthalmopathy).

Alternative therapies as thermal ablation of TA and TMNG can be considered in select patients in whom RAI, surgery, and long-term anti-thyroid drugs are inappropriate, contraindicated, or refused, but this approach obtained no recommendation at present [68].

### Surgical treatment of euthyroidism

Surgery is the only option that guarantees a definitive treatment with removal of the goiter despite the risk of specific complications. Main indications for surgery include compression symptoms, suspicion for malignancy, prevention of complication from progressive enlargement or mediastinal extension (with complications related to tracheal deviation and narrowing, superior vena cava syndrome) and occasionally for cosmesis. Surgery should also be considered in nodules that develop suspicious US changes or increase in volume and become symptomatic. The preferred extent of resection is lobectomy for benign uninodular goiter and total thyroidectomy for bilateral multinodular goiter.

- Unilateral nodular benign disease (negative cytology; normal contralateral lobe): lobectomy plus isthmectomy [3, 24]
- Unilateral nodular disease with cytological evidence of indeterminate nodules, with normal contralateral lobe: lobectomy and if available prior molecular testing [8, 71, 72]



- Multinodular goiter: total thyroidectomy [3, 24]
- Asymptomatic nodules with modest growth and negative cytology and asymptomatic cystic nodules may be followed conservatively without intervention [3].

### Surgical treatment of substernal goiter

By definition, a substernal goiter extends into the mediastinum by at least 50% of its volume. The incidence is reported to be between 1 and 30%. It is classified as primary (very rare, originating from ectopic mediastinal thyroid tissue, with no connection to the cervical thyroid gland, and blood supply from branches of the aorta, the innominate artery or the internal mammary artery) or secondary (originating from the thyroid, with preserved vascular, parenchymal or fibrous connection to the gland) [73, 74].

Being most of the mediastinal goiter connected to the cervical thyroid gland, usual surgical approach consists in a total or near total, bilateral or mono-lobar retro-sternal thyroidectomy, according the bilateral or only mono-lobar thyroid involvement, through a cervical access, which is possible in 90 % of cases [73–75].

Additional sternotomy and/or thoracotomy are necessary for malignancies with local infiltration of the mediastinum, for rare cases of primary substernal goiter or when the mediastinal and/or retrovascular component of the goiter is such that to make removal through the cervical incision dangerous or impossible. Other factors favouring additional extra-cervical accesses include potential fibrosis from prior radiation or surgery; caudal extension below the arch of the aorta or involving the posterior mediastinum and ectopic mediastinal goiter not connected to the cervical gland [24, 76]. Surgical procedures are burdened with a greater incidence of complications due to complex vascular control and risk of haemorrhage, tracheal compression with risk of severe tracheomalacia and modification in normal anatomical landmark for inferior laryngeal nerves.

Neck CT scan imaging for suspected substernal goiter is recommended preoperatively to quantify the caudal extent with a 3D reconstruction and to confirm tracheal compression [24].

### Surgical treatment of thyroid malignancy

Adequate surgery is the most important treatment variable influencing prognosis. There is evidence to recommend total thyroidectomy in most cases, but lobectomy may be considered for intrathyroidal, uni- or multiple unilateral small tumors.

- Differentiated carcinoma: surgery should ensure removal of the primary tumor and of disease that has extended

beyond the thyroid capsule, and clinically metastatic lymph nodes with contained incidence of postoperative complications. The extent of thyroidectomy (hemithyroidectomy versus total thyroidectomy) for differentiated thyroid carcinoma is still debated. Total thyroidectomy ensures good local control of cancer by removing even microscopic tumor foci (that are frequent and often bilateral), facilitates subsequent RAI treatment and allows adequate follow-up. Despite total thyroidectomy is still considered the standard of care for most of thyroid malignancy, there is no definitive evidence supporting a more aggressive surgical approach in terms of recurrence risk reduction and absolute survival [3, 23, 25, 77].

Due to the concern for over-treatment, surgical management of thyroid cancer has evolved in recent years. There is clear evidence supporting an appropriate risk assessment to recommend more aggressive interventions for high-risk patients and less aggressive therapies for low risk patients. The surgical treatment of the low-, intermediate-risk DTC (1–4 cm) remains still controversial. After careful patient selection hemithyroidectomy, in patients with DTC with diameter < 2 cm without other specific risk factors, could be a safe alternative [3, 78, 79].

Elderly or fragile patients might benefit of this tailored approach despite tumor risk factors must be always considered [80].

In the scenario of increased overall rate and early diagnosis of thyroid cancer, after accurate patient and tumor selection, recent evidence supports an active surveillance instead of up-front surgery in the management of low-risk thyroid microcarcinoma to avoid overtreatment and complications from unnecessary surgery [81–83].

For lymphadenectomy, please refer to the appropriate section.

- Medullary carcinoma

Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor originating from the parafollicular which presents in both sporadic (70 %) and hereditary (30 %) forms, either isolated or as part of a multiple endocrine neoplasia: MEN 2A or Sipple's syndrome (in association with pheochromocytoma and hyperparathyroidism); MEN 2B or Gorlin–Steinert syndrome (in association with pheochromocytoma, ganglioneuromatosis and marfanoid habitus). Demonstration of calcitonin (CT) increased value is mandatory for the diagnosis. All patients with MTC should be offered genetic counselling due to the evidence that RET proto-oncogene mutations are detected in 90% of MTCs and are considered the predominant drivers of these tumours. RET mutations may occur both sporadically or can be inherited as germline

events associated with familial MTC or with the multiple endocrine neoplasia syndromes.

There is a strong recommendation for total thyroidectomy plus central node dissection, whatever values of CT are detected, being surgery the only potentially curative treatment. More extended lymphadenectomies are related to CT values and ultrasound findings (for lymphadenectomy, please refer to the appropriate section).

In multiple endocrine neoplasia syndromes, a personalized strategy must be defined, in a multidisciplinary setting, to plan the priority of treatment of the associated tumors, mostly considering the concomitance of a pheochromocytoma and the age of the patient. Usually, adrenalectomy must be performed prior to thyroidectomy, and parathyroidectomy during thyroidectomy [1, 25, 84].

#### – Undifferentiated or anaplastic carcinoma

Undifferentiated or anaplastic carcinoma is a rare thyroid tumor associated to poor prognosis in most cases (median survival of approximately 5 months). Advanced disease with extensive local infiltration and/or distant metastases are typically detected at the clinical onset. Approximately 10% of patients with ATC present with only an intrathyroidal tumor, whereas 40% have extrathyroidal invasion and/or lymph node metastasis, with the remainder of patients presenting with widely metastatic disease [25, 85].

When anaplastic carcinoma is suspected, clinical and instrumental assessments of disease by a multidisciplinary team (surgeon, endocrinologist, pathologist, oncologist, radiation oncologist, radiologist) are pivotal for the evaluation of treatment options and advantages/disadvantages of the proposed treatments which must always be discussed with the patient with a clear focus to the patient's goals of care and life expectancy [25, 85].

Endoscopic evaluation (both fiberoptic laryngotracheoscopy and bronchoscopy, often also esophagoscopy and if indicated endoscopic ultrasonography) and imaging with CT scan or MRI with contrast and PET scan are fundamental for a precise assessment of local invasiveness and to exclude the presence of distant metastasis. Evaluation of airway status is of primary importance especially in order to schedule palliative treatment for this life-threatening complication.

The surgical treatment can achieve three possible options: palliation, prevention of future complications or curative intent. The option of neoadjuvant and/or adjuvant therapy must affect the decision for a possible surgical resection and the approaches and treatments must be always planned as multimodal [25, 85].

All anaplastic thyroid cancers are considered as stage IV (AJCC/UICC): stage IVa and IVb patients may be

potential candidates for a multimodal treatment including a more or less radical surgical resection associated with radio- and chemotherapy, which, in some cases, allows subsequent surgical re-exploration for local disease control. In patients with stage IVc, treatment options remain limited and controversial. Treatment is mostly palliative (tracheostomy or tracheal esophageal stent), with the intent of improving patients' quality of life as much as possible and guarantee sustainable end-of-life conditions according to the patient's preferences.

Surgical resection with curative intent should be offered to patients with loco-regional disease only if complete tumor resection can be achieved with minimal morbidity being R0/R1 resections independently associated with longer overall survival.

Surgical treatment usually consists in [25, 85]:

- a total thyroidectomy or a near-total thyroidectomy (48.6%) with associated lymphadenectomy, with only a limited group of patients (1.7%) receiving a laryngectomy/pharyngectomy as part of the procedure.
- The role of thyroid lobectomy is still debated with insufficient data regarding the clinical outcome. This option can be only considered in patients with localized and resectable ATC (normal contralateral lobe on preoperative ultrasound) and documented injury to the ipsilateral recurrent laryngeal nerve, or no identification of the ipsilateral parathyroid glands.
  - ATC extensively involving the upper aero-digestive tract or major vascular or mediastinal structures, is generally not considered for surgical resection. However, tailored treatment should be considered on individual basis when radical resection with appropriate reconstruction can be achieved supported by expected benefit from associated treatments such as chemoradiation. However, it must be considered that surgical intervention may delay external beam radiation or systemic chemotherapy because of wound complications.
  - Pre-emptive tracheostomy placement is not recommended in patients without impending airway compromise. It is instead recommended in case of symptomatic patients or as prevention of laryngeal and tracheal edema before radiotherapy.
  - For incidental ATC limited to the thyroid, a total thyroidectomy is the appropriate treatment and either lobectomy can be considered since there are no data that demonstrate a difference in disease free survival or survival based on the extent of thyroidectomy.

For lymphadenectomy, please refer to the appropriate section.

### Thermoablative treatment

Ultrasound-guided thermoablative treatment (TA) procedures are used as alternative treatment in selected clinical cases. The international guidelines have standardized their use [86, 87]. TA procedures are well tolerated by the patient but require specific operator training. The TAs are radiofrequency ablation (RFA), laser ablation (LA), microwave (MWA) and high intensity focused ultrasound TA (HIFU). Symptomatic benign nodules, hyperfunctioning nodules, microcarcinomas and recurrent lymph node metastases can be treated [88–94]. TA treatments induce a reduction in nodular volume and an improvement in symptoms. Over the years it is possible to have a volumetric increase in the lump that may require re-treatment or surgery [95, 96]. LA and RFA are currently the most used techniques, whereas MWA and HIFU are still under study.

### Selection criteria for patients with benign symptomatic nodular lesion

Symptoms are compression, cosmetic damage, and tracheal deviation. Before TA, patients will have to perform two FNABs of the lesion with benign outcome (TIR2/Thy2) [86, 87, 97]. Symptoms are influenced by the location of the lesion, the circumference of the neck and other factors that cannot be objectively assessed [97]. Therefore, according to the international guidelines [86, 97], the TA of benign nodules should be considered for patients with nodules with a diameter  $\geq 30$  mm or with a minimum volume of 6 ml who complain of local discomfort. Treatment of asymptomatic lesions is not recommended.

### Selection criteria for patients with compressive multinodular goiter

In patients with compressive multinodular goiter, TC or MRI should be performed and TA should be limited to cases with a dominant nodule not suitable for surgery due to concomitant diseases or at the explicit request of the patient [86, 98].

### Selection criteria for patients with hyperfunctioning nodule

In hyperfunctioning thyroid nodule, a  $^{99}\text{Tc}$ -scintigraphy should be performed. In Plummer's adenoma less than 10 ml the patient can be subjected to TA [3, 86].

### Selection criteria for patients with microcarcinoma

Literature suggests active surveillance of microcarcinomas only in selected patients [3]. A valid alternative is TA in all those patients who refuse surgery and who experience active surveillance with anxiety and concern [99]. Patients undergoing TA showed a significant reduction in lesion volume, negative cytology for malignant cells at follow up and no statistically significant difference in the risk of lymph node recurrence compared to the surgery group [99–104].

### Selection criteria for patients with lymph node recurrence from papillary carcinoma

Lymph node recurrences are treated with surgical excision, metabolic radiotherapy, TA and thyroid suppressive hormone therapy [98–104]. TA can be used in the treatment of lymph node recurrences in patients who refuse surgery or who suffer from comorbidities such that surgery is not recommended [87, 96, 97].

Localized treatment with TA is useful in patients with a single metastasis, in those with metastases at high risk of local complications and should be performed in patients prior to the initiation of any systemic treatment [3]. In case of ultrasound suspicion, an FNAB with dosage of Thyroglobulin in the eluate should be performed [3]. In addition, a contrast spiral CT and an  $^{18}\text{F}$ FDG-PET/CT should also be performed to allow for adequate mapping, preoperative localization and staging [3, 104]. Treatment of single lymph node recurrences with TA resulted in a 55–95% reduction in lesion volume and complete disappearance of metastatic foci in 40–60% of cases [3, 104]. TA can be considered a valid alternative in high-risk surgical patients or those who refuse surgery [3].

### Regional neck nodes dissection

#### Differentiated thyroid cancer

Regional nodal disease is reported in 30–60% of patients with Papillary Thyroid Cancer (PTC) at diagnosis, even in clinically node-negative (cN0) patients.

All the patients undergoing surgery for thyroid cancer should undergo a thorough preoperative assessment of

cervical lymph nodes, including central and lateral compartments. High-resolution ultrasound is sensitive and specific in detecting lymph node metastases and may identify non palpable lymph node metastases in up to a third of patients with papillary thyroid cancer.

The neck computed tomography or magnetic resonance imaging is not part of the routine initial evaluation. Still, it is recommended for patients with suspected advanced disease, especially in extensive lateral neck disease and for areas not accessible by ultrasound [105–109].

The most common site of lymph node metastasis from PTC is the central compartment, followed by the jugular chain [109].

Prophylactic central lymph node dissection (PCLND) in clinically node-negative (cN0) PTC patients is still a controversial issue [108, 109].

The potential benefits of (PCLND) include [27]:

- Reducing the risk of central neck recurrence.
- Increasing the accuracy of pathologic staging to guide adjuvant RAI therapy.
- Improving the accuracy of thyroglobulin surveillance during long-term follow-up.

It has been demonstrated that PCLND may increase the rate of complications, including hypoparathyroidism and recurrent laryngeal nerve (RLN) injury. In contrast, no high-level scientific evidence confirms a significant impact on the oncologic outcome [1, 109–113].

To date, PCLND in PTC is not routinely indicated [26, 114].

PCLND should be considered for PTC patients who present with advanced tumours (T3 and T4), bilateral or multifocal tumours, or known lateral cervical neck disease [3, 115].

Recently a more limited PCND, including removal of pre-laryngeal, pretracheal and paratracheal nodes on the side of the tumour, was proposed in selected patients with clinically unilateral DTC [116]. For PTC patients presenting with clinically involved lymph nodes in the central neck (cN1), therapeutic central neck dissection is recommended [117–121].

The central compartment includes level VI and VII lymph nodes. In level VI, the anatomic boundaries are the hyoid bone (superior), common carotid arteries (laterally), sternal notch (inferior), and prevertebral fascia (posterior). Level VII include the lymph nodes below level VI and are bordered by the innominate (brachiocephalic) artery.

Nodal metastases of the central compartment involve most frequently four major nodal basins: prelaryngeal (Delphian), left paratracheal, right paratracheal, and pretracheal. Out of there, parapharyngeal, retropharyngeal, retro

oesophageal and upper mediastinal areas are more rarely involved.

The central neck dissection includes a comprehensive and compartmental dissection and may be unilateral or bilateral. Unilateral central neck dissection involves completely removing unilateral paratracheal nodes and pretracheal and prelaryngeal lymph nodes. Bilateral dissection includes the removal of pretracheal, prelaryngeal, and bilateral paratracheal lymph nodes.

Node picking of only the macroscopically involved nodes is not recommended [122–125].

### Lateral neck

Clinically apparent lymph node metastases to the lateral neck are present in approximately 20–30% of patients at presentation.

Metastatic spread is mainly observed in levels III, IV, IIA, and VB and occasionally in the IIB and VA [126]. Skip metastasis to the lateral neck without central compartment can be seen approximately in 8.7–21.8% of patients [127–129].

Optimal treatment of patients with metastatic thyroid cancer requires the removal of macroscopic clinical cervical lymph node metastases at the time of initial surgery.

Therapeutic lateral neck dissection is recommended for patients with lateral lymph node metastasis proven by biopsy and/or thyroglobulin washout. Prophylactic lateral ND is not indicated for PTC.

The lateral neck dissection should be a compartment-based selective neck dissection of the levels IIA, III, IV, and V. Comprehensive clearance of these levels is associated with a lower risk of recurrence [130, 131]. To reduce the risk of spinal nerve injury and due to the low likelihood of lymph node involvement, the level IIB dissection is best avoided unless there are suspicious lymph nodes at level IIB or bulky disease at level IIA. Similarly, routine dissection of level VA is generally unnecessary and is only dissected when there are clinically apparent lymph node metastases [106, 130]. More selective lymph node dissection, such as levels III, IV or levels IIA, III, IV, may be considered in patients with well-differentiated thyroid carcinoma with limited lateral neck lymph node metastases without other risk factors [132].

Lateral ND can be associated with significant complications. The most frequent permanent complication is paresthesia of the lateral neck and ear, which results from injury to the greater auricular nerve and sensory cervical root branches. Up to 11% of patients undergoing lateral neck dissection develop chronic neck pain that can be secondary to injury of the accessory nerve or the cervical root branches during dissection in the posterior triangle. Temporary or permanent injury to the eleventh cranial nerve (accessory spinal nerve) can occur in 6% to 20% of cases, resulting

in shoulder drop and inability to raise the arm. This risk is increased when levels IIB and VA are dissected. Less common complications of lateral neck dissection include injury to the phrenic nerve and the sympathetic chain, and these occur in less than 1% of patients [59, 133].

### Medullary thyroid carcinoma

The initial surgical approach depends on preoperative serum calcitonin levels and neck imaging findings.

In patients with medullary cancer, sporadic or familial, without evidence of nodal disease, total thyroidectomy with a prophylactic bilateral central neck dissection at the initial operation is the standard treatment [25–84, 134].

Preoperative screening for pheochromocytoma and hyperparathyroidism is recommended for all patients with MTC [133].

Initial management of the image negative lateral neck compartments in MTC patients remains controversial.

The central neck nodal status and preoperative calcitonin levels may predict the probability of lateral neck involvement and guide treatment of the lateral neck compartments [135, 136].

In patients with medullary thyroid cancer and no evidence of neck metastases on ultrasonography and no distant metastases, lateral neck dissection (levels II–V) may be considered based on serum preoperative calcitonin levels. Elective ipsilateral lateral neck dissection might be performed if the basal calcitonin is above 200 pg/ml and if calcitonin levels are greater than 400 pg/ml, even contralateral lateral neck dissection has been proposed. However, this topic is still debated and these recommendations are not practised routinely by most surgeons [84, 137].

In conclusion, based on current practice guidelines and available evidence patients with MTC metastatic to the cervical lymph nodes should have a total thyroidectomy, dissection of the central compartment and comprehensive dissection of the involved lateral neck compartments (levels II–V).

When only the ipsilateral lateral neck compartment is positive at preoperative workup, contralateral neck dissection is recommended if the basal serum calcitonin level is greater than 200 pg/mL.

Lateral neck dissection, when indicated, should be comprehensive, including levels from II to V [25, 84].

### Anaplastic thyroid cancer

The incidence of neck lymph node metastases is high in anaplastic thyroid carcinoma. Lateral neck dissection should include levels II–V with central compartment clearance when surgery is performed with radical intent [1, 137].

## Postoperative complications and their management

For a correct management of patients undergoing thyroid surgery, it is essential that medical and nursing staff know all post-thyroidectomy complications and time of onset, to promptly treat especially those that can endanger patient's life, such as haemorrhage, with compressive hematoma and bilateral paralysis of recurrent laryngeal nerve, with acute respiratory failure. Another complication that must be recognized quickly, is hypocalcemia, because, if severe, it can cause tetanic crisis.

Complications that do not immediately endanger patient's life are unilateral recurrent laryngeal nerve paralysis and External Branch of the Superior Laryngeal Nerve (EBSLN) injury.

### Prevention and management of complications haemorrhage with compressive hematoma

Post-thyroidectomy haemorrhage with compressive hematoma is a very serious complication that can lead to death of the patient [19]. It occurs at a rate ranging from 0.1 to 2% of patients, in a quarter of cases with the need to reopen the wound at the patient's bed. Almost all cases occur in the first 6 h after the intervention, about 20% between 6 and 24 h postoperatively, and only in a few anecdotal cases after 24 h [138, 139].

Risk factors for bleeding have been identified, some related to the patient, others to the disease, others to the intervention and others to the surgeon. Those related to the patient, concern coagulation pathologies (such as hemophilia, liver diseases, chronic renal failure, etc), the intake of anticoagulant and antiplatelets drugs and the sex. The male sex was reported by some Authors as at greater risk than the female one [138]. About disease at greater risk of post-thyroidectomy bleeding, Graves's, substernal and recurrent goitre have been reported [56, 140].

As regards the intervention, hemithyroidectomy is at higher risk than total thyroidectomy [139]. Risk factors related to the surgeon are strictly dependent on his experience: the greater the number of thyroidectomies performed, the less the risk of bleeding [138].

Fundamental aspect to prevent bleeding is an accurate and precise hemostasis technique. Hemostasis can be obtained in different ways. The conventional technique consists in the ligation/clamp and section of the vessels, with or without cautery. About cautery it may be used for small vessels. It is better to use a bipolar than a monopolar one, because the first prevents heat loss, avoiding adjacent structures such as parathyroids and inferior recurrent laryngeal nerve injuries. "Energy devices", so defined because they use different

forms of energy such as radiofrequency or ultrasound or hybrid systems that combine both energy modalities, have proved to be very useful for thyroid surgery, without an increased risk of postoperative bleeding [141, 142]. As well as an accurate hemostasis, to reduce the risk of bleeding, the execution of a manoeuvre by the Anaesthetist that simulates a “Valsalva”, may help to highlight a small venous bleeding. Some Authors also suggest not to completely close pre-thyroid muscles and to leave an opening, to facilitate spontaneous decompression in case of bleeding [19]. The routine use of drain is not recommended. Its use should be considered on a case basis. Recent meta-analyses have shown that the use of suction drains does not prevent neck haematoma, and that, conversely, the postoperative stay is longer, and that the incidence of wound infection is higher [143, 144]. In addition, the use of local haemostatics is still controversial, but considering the findings currently available from two meta-analyses, their use has not shown advantages in reducing the rate of clinically relevant bleeding, while increasing the rate of wound infection [145, 146].

If hemorrhage with compressive hematoma develops, it must be diagnosed quickly. For this reason, the nursing staff must check the neck and dressing frequently in the first 24 postoperative hours, with particular attention to the appearance of neck swelling and, if present, to the drain. This must not be empty, because it could be blocked by clots, or full, as it indicates excessive blood loss. The nurse must alert the surgeon in case of neck swelling, exceeding blood loss from the drain, onset of restlessness, and dyspnea. In case of symptomatic hematoma, immediate reopening of the wound, in severe cases even bedside and before reintubation, quick reintubation, and surgical revision are necessary. The removal of clots and the revision of hemostasis are the definitive treatment for progressive and symptomatic hematoma. The observation is possible only in the case of small self-limiting hematomas.

## Hypoparathyroidism

Hypoparathyroidism is the most frequent complication after bilateral thyroid surgical interventions and consists in decreasing both parathyroid hormone (PTH) and calcium serum levels, below the lower reference value. This complication may be transient or definitive, depending on whether it resolves within 6 months or not [147].

The incidence of post-thyroidectomy hypoparathyroidism is variable in literature, ranging from 19 to 39% the transient and from 0 to 15% the definitive [148].

The main cause of hypoparathyroidism is the trauma caused by surgery, which can lead to devascularization of the parathyroid glands or to accidental removal of one or more parathyroids, from 3.8 to 9.7 % in literature [149, 150]

A long duration of the surgical procedure and hypothermia may be further factors favouring this complication.

In addition to surgery, other risk factors for hypoparathyroidism linked to the disease and to the patient have been identified, such as Graves’, thyroiditis, retrosternal goiter, cancer with need of central neck dissection and the female sex.

A frequent condition is hypocalcemia with PTH values in the normal range. In these cases, metabolic factors, such as vitamin D deficiency and hyperthyroidism, have been implicated to explain the lowering of calcium levels, despite the normal PTH [151].

Surgeon’s experience minimises the risk of hypocalcemia, favouring the recognition of parathyroid glands, that could be confused and consequently damaged, with fat, thyroid nodules, and lymph nodes. A precise surgical technique consists in dissection of parathyroid glands, remaining as close as possible to the thyroid capsule, to preserve their vascularization.

This may be improved using loop magnification (4×). The use of auto- and immune-fluorescence methods has been proposed by several Authors both to better identify parathyroid during surgery and to predict postoperative hypoparathyroidism [152, 153] even if not all authors agree on the real usefulness of the procedure [154]. In case of venous congestion of a parathyroid gland, it would be advisable, to make incisions on the capsule, to facilitate blood outflow. When a parathyroid is accidentally removed, it is indicated to re-implant it, reduced in small fragments of 0.5–1 mm, in pockets of ipsilateral sternocleidomastoid muscle, after extemporaneous histological examination [19, 155].

Near-infrared autofluorescence (NIRAF) imaging is a promising technique and should be employed when available. This technique exploits the intrinsic fluorescence produced by parathyroid glands when exposed to a source light with a specific wavelength (820–830 nm) without the use of a contrast agent. Different studies have reported a significant decrease in both transient and definitive post-operative hypoparathyroidism [156, 157].

The lowest calcemia values are usually observed 24–72 h after thyroidectomy. Several methods have been proposed to predict early, within the first postoperative day, which patients will develop hypocalcemia. The combined dosage of post-operative PTH and serum calcium levels proved to be valid in the decision of which patients to treat [158, 159].

In case of hypocalcemia (calcium < 8 mg/dL) with normal PTH the patient can be treated with calcium carbonate at a variable dosage from 2 to 6 g per day, in at least three administrations, or the equivalent of Calcium citrate. When hypocalcemia is associated with low levels of PTH, in addition to oral calcium supplementation, it is also necessary to administer calcitriol at a variable dosage from 0.25 to 0.5 mcg, once or twice a day. In the event of severe symptomatic

or asymptomatic hypocalcemia with calcium serum levels < 7.0–7.5 mg/dL, or drop in calcium levels despite oral calcium support, intravenous calcium is required: 2 g of Calcium gluconate diluted in 250 ml of normal saline, once or twice a day [158]. In these cases, it is also important to measure magnesium levels, because magnesium depletion reduces PTH secretion and activity. If it is < 1.6 mg/dL, in patients with normal renal function, it is necessary to supplement it with 400 mg of Mg oxide once or twice daily. Levothyroxine should be taken one hour before or three hours after calcium supplementation [160, 161].

### Temporary or permanent damage to the recurrent laryngeal nerve and the external branch of the superior laryngeal nerve

Unilateral paralysis of the vocal cords (VC) as a result of unilateral paresis of the recurrent laryngeal nerve (RLN) can lead to a significant reduction in quality of life with dysphonia and dysphagia, which has consequences especially for young patients. In addition, shortness of breath may occur during speech due to uncontrolled air leakage. While improvement of the voice can be achieved with speech therapy in unilateral VC paresis, patients with bilateral RLN paresis are significantly restricted in their daily life and are disabled in the long term.

Bilateral RLN palsy is often associated with respiratory distress syndrome and may require permanent tracheotomy or glottis dilating surgery [62]. The risk of tracheostomy for bilateral RLN palsy averages 30%, with another 21% requiring other acute airway interventions. Thus, overall, 50% of patients with bilateral RLN palsy require airway intervention.

The true incidence of postoperative transient RLN complications appears to be approximately 3% to 12%. The incidence of long-term RLN complications such as permanent morbidity remains unknown. The same is true for the incidence of bilateral RLN palsy, whether transient or permanent, is unknown.

RLN palsy leads the world in the incidence of forensic litigation after thyroid surgery [62].

Pre- and postoperative laryngeal examination is a gold standard for RLN management, along with the surgeon's experience, training, routine exposure, identification of the nerve, and perfect knowledge of the surgical anatomy of the RLN.

For embryological reasons, the anatomical course of the right and left RLN differs. The right RLN is shorter because it winds around the (right-sided) brachiocephalic truncus, and the left RLN is longer because it winds around the dorsal aortic arch. Because of the aforementioned embryologic-anatomic features, the right RLN runs obliquely from lateral

caudal to mediocranial, whereas the left RLN runs more vertically and parallel to the esophagotracheal axis. The different, embryologically determined nerve anatomy on both sides is also reflected in the different frequency of the following anatomic features and anomalies

### Tuberculum Zuckerkandl

Tuberculum Zuckerkandl, seen to varying degrees in approximately 60% of thyroidectomies, is more common on the right side than on the left side above [62]. The RLN usually runs dorsal to the tubercle of Zuckerkandl, but it may cross the tubercle or only the anterior branch of the nerve crosses the tubercle.

### Non-RLN

A non-RLN is found in about 1.5% of thyroid surgeries and, for embryological reasons, is almost always on the right side, and only extremely rarely (in the case of complete situs inversus) on the left side.

In addition to these two atypical nerve courses, which occur with varying frequency on both sides, there are variants of the RLN course on both sides related to the following anatomic structures and features of thyroid pathology:

### Relationship between RLN and inferior thyroid artery (ITA)

In the area where the ITA crosses with the RLN, the RLN comes in close proximity to the thyroid gland. More than 20 positional variants of the RLN in relation to the upper and lower branches of the ITA have been described. There are three main variants that can be considered: the retrovascular, antevascular, and intervascular courses. An antevascular course is more commonly observed on the right side, and a retrovascular course is more commonly observed on the left side. When a CT-scan is available, a careful evaluation for an aberrant right sub-clavian artery (arteria lusoria) should be carried out to evaluate the presence of a non-RLN.

### Ligamentum berry

The closest positional relationship between the RLN and the thyroid organ capsule is in the region of the ligament of Berry. Both intraligamentous and intrathyroidal location of the RLN may occur.

## Extralaryngeal branches

Based on anatomic studies, extralaryngeal branches of the RLN occur in approximately 60–90% of nerve courses; there are usually 2, rarely 3, branches of the RLN, which usually arise from the main trunk above the junction and divide before entering the larynx. Isolated paralysis of the dorsal or ventral ramus is extremely important for surgery because either closure (ventral branch) or opening of the glottis (dorsal branch) is compromised.

### Preoperatively predictable RLN risk

Anatomic criteria for determining patients at high risk for thyroid surgery have been described. Increased risk for RLN palsy is detectable preoperatively when locally advanced cancer is diagnosed or a large retrosternal goiter is detected on imaging. Graves' disease, Hashimoto's disease, de Quervain's disease, or Riedel's thyroiditis also indicate a potentially increased risk of RLN palsy. The risk of bilateral paralysis is particularly high in the presence of preexisting unilateral paralysis.

### Preoperatively unpredictable RLN risk

Preoperatively unpredictable risk situations that can only be detected intraoperatively are one of the main reasons for using neuromonitoring (IONM) not only selectively but also routinely. Examples of intraoperative risk situations are: (1) atypical RLN pattern anterior to the thyroid gland; (2) RLN anterior to Zuckerkandl's node; (3) fixed, spread, or trapped RLN with capsular association through fascial bands; (4) vascular or goitrous lesions; (5) invaded RLN; (6) posterior ligament of Berry's nerve; (7) thin RLN (< 1 mm); (8) Branching of the antevascular RLN; or (9) non-RLN, which occurs in approximately 1.5% of thyroid surgeries. Atypical courses of RLN are observed in approximately one quarter of thyroid surgeries.

Finally, with the increasing use of IONM, there seems to be a need to adjust the resection strategy in case of intraoperative loss of signal (LOS) of the first operated side in planned total thyroidectomy. If a true LOS is confirmed, identification of the site of the lesion, i.e., mapping of the neural injury point, is recommended and then consideration of the optimal contralateral surgical timing is suggested. The option to abort surgery is suggested.

In addition to knowing normal anatomy and anatomical variants of the RLN, to prevent injuries, some technical measures are important. First is the visualisation of the nerve along the entire course in the operating field, up to the entrance into the larynx. It is important to keep the operating field bloodless, to avoid excessive traction on the nerve and to avoid the use of heat sources, such as cautery and

energy-based devices, near it. In the case of RLN section, recognized intraoperatively, immediate repair is possible. The reconstruction does not allow the resumption of the motility of the vocal cord motility, but it seems to improve its tone and to facilitate the resumption of the voice, avoiding aspiration. There are several possibilities for nerve reconstruction and consist of microsurgery techniques. RLN reconstruction may be direct through a simple end-to-end fascicular anastomosis, if the lesion may be repaired without tension and the damaged section is less than 5 mm. When the section is more than 5 mm, anastomosis between the injured nerve and the ansa cervicalis nerve is considered the most suitable method. Direct reinnervation of thyrohyoid muscle has shown good results. Injection laryngoplasty with different materials, is a procedure with the aim of improving glottal closure and reducing the space between the paralyzed vocal fold and the normal. In all cases speech therapy is the first measure to be taken to restore the voice [162, 163].

In case of bilateral RLN injury and consequent bilateral vocal cord paralysis, at the time of extubation, the patient may develop acute respiratory failure, if the paralysis is in adduction. This situation requires reintubation and immediate tracheostomy should be avoided. The patient should be kept intubated for 24 h. After 24 h an extubation attempt under fibroscopic control should be made, with evaluation of the motility of the vocal folds. If the bilateral in adduction paralysis persists, another 24 hours of intubation are indicated. The tracheostomy is indicated if the condition with respiratory distress persists further. The prolonged safe extubation approach gives the possibility to reduce the need for tracheostomy up to 85% of cases [164].

In case of definitive paralysis, various procedures have been proposed, and one of the most used is posterior laser cordectomy [165].

In case of bilateral vocal fold paralysis in paramedian position, with adequate respiratory space, tracheostomy is not necessary. Bilateral paralysis of the vocal cords, especially in this situation, is associated with swallowing disorders, with risk of inhalation. The use of thickening substances to liquids can limit this risk. Damage to the external branch of the superior laryngeal nerve (EBSLN) causes changes in pitch and vocal range. Identification of this nerve can be difficult. The technical trick of ligating the branches of the superior thyroid artery near the capsule, with slight lateral and caudal traction of the upper pole, may reduce the risk of nerve injury. Intraoperative neuromonitoring with stimulation and detection of the EBSLN before upper pole dissection may allow a higher rate of nerve preservation [30].



## Hospital discharge and patient information

It is recommended to inform patients of their expected date of discharge, 24-h in advance. On the expected day, and after checking the normality of the blood pressure, wound care, with no symptoms in the neck, bulging, or cervical bruising, and laboratory assessment of parathyroid function, instructions on how to care at home are provided, as well as how to control pain, ideally with no more than three analgesics [166].

### Short-day surgery criteria

Day hospital discharge has been described since 1980s and proved to be safe, with high patient satisfaction rate in selected cases [167].

General considerations to be applied for short day surgery are listed below, and require a standardized preoperative selection, and interdisciplinary collaboration between the surgeon, anaesthetist and nursing staff:

- I. patients need to understand the implications of surgery and the planned follow up;
- II. patients need adult accompaniment at their residence;
- III. patients should stay close to the hospital facilities easily accessible within a maximum of 1 h in case of urgency;
- IV. patients should be able to eat, without nausea, vomiting, or other adverse reactions;
- V. patients should have been sat on a chair;
- VI. patients voided.

According to the common experience in the affiliated Italian endocrine surgical units, the SIUEC experts' panel recommend against short stay modality in whatever thyroid surgery.

### Hospital discharge summary

A comprehensive clinical report, with a copy included in the patient's chart, should be given to the patient on the discharge day and addressed to the primary care physician. The attending physician who discharges the patient on the day should sign the report, containing also direct phone number of the hospital and clinic.

Recommended information to be included in the discharge summary are listed below:

1. date of admission and first diagnosis;
2. main tests performed during the hospital stay, focusing on those with an altered result and those requiring further investigation;

3. summary of the operative note, reporting the day and the type of surgery, any intraoperative difficulties encountered and, if performed, reimplantation of parathyroid tissue; detailed information on drains coming from the incision, as well as the type of wound closure (stitches etc.) for outpatient wound care;
4. description of the postoperative course, specifying presence or absence of any known complications, i.e. hemorrhage, dyspnea, dysphagia, dysphonia, hypocalcemia, etc.;
5. pharmacological treatments administered to the patient and final pathology report, if available;
6. recommended diet and daily activity exercise;
7. medications on discharge, clearly indicating posology and administration way; if necessary specify thyroid hormone and calcium supplementation;
8. education on how to promptly recognize hypocalcemia-related symptoms;
9. recommended and/or scheduled clinical and/or diagnostic follow-up, as well as eventual radio-iodine treatment in case of cancer;
10. follow-up ENT/phoniatrics, in case of dysphonia and/or rehabilitation program if altered vocal fold mobility is documented.
11. Following thyroidectomy L-thyroxine should be started at a daily dose appropriate for the patient's weight (0.8 mcg/lb or 1.7 mcg/kg), and serum TSH measured 6–8 weeks postoperatively. Following thyroidectomy, specifically indicated for hyperthyroidism, a specific monitoring of calcium levels must be undertaken and calcium and calcitriol supplementation administered based on biochemical results.

## Outpatient care and follow-up

The Endocrine Surgery outpatient clinic should be the referral centre for first assessment of patients, either sent for consultation by the primary care physician, the endocrinologist or as a result of histopathological findings.

If during the consultation the final judgement is admission to hospital care, detailed information regarding treatments options should be provided, preferably in the form of a leaflet to allow the patient to elaborate further. These would consist of:

- I. Surgical indications and possible alternative medical treatments;
- II. Advantages of the surgical treatment over alternative therapy and risks related to the intervention in the short and long-term.

At the end of the consultation, it is good practice to summarise the outcome in a medical report including the following:

- (a) General medical condition, comprehensive of past and present medical history, or any condition potentially requiring special care;
- (b) physical examination;
- (c) diagnosis;
- (d) proposed treatment;
- (e) additional laboratory test and/or imaging (if necessary);
- (f) agreement or disagreement with other opinions from colleagues who previously assessed the same patient (if any report is provided by the patient during the consultation);
- (g) postoperative fiberoptic laryngoscopy is mandatory if dysphonia appears, and eventually followed by speech therapy, according to ENT' and/or phoniatrist's judgement.
- (h) In the follow up endocrinological consultation is recommended.

For patient with thyroid carcinoma a multidisciplinary approach [168] including the surgeon, the endocrinologist, the nuclear medicine physician, the pathologist and the radiology, the molecular biologist and the radiation oncologist, is recommended to provide a comprehensive and multimodal management of the disease, as diagnosis and treatment could be complementary in different phases and patients, especially in complex cases [169].

On the basis of cancer risk recurrence, in patients with differentiated carcinoma, postoperative radioiodine therapy indication [170] may be posed, therefore risk stratification appears essential, in fact controversy for its use still remains in intermediate-risk and some low-risk patients to establish the most appropriate thyrosuppressive therapy, as well as intensity and frequency of follow-up.

Depending on the clinical course of disease and response to therapy, the risk of recurrence and mortality may vary over time. Reclassification of risk based on the information obtained during follow-up is valuable, and it is essential to ensure proper management. Dynamic risk assessment should be used to guide all aspects of thyroid cancer management, from the beginning, before a definitive diagnosis is made, and continuing through the final follow-up visit [171].

Registry data are crucial in defining good practice in patient evaluation, benchmarking, and improving the overall quality of the process; they also allow transparency of practices and provide an easy reference for future comprehensive assessment of long-term cancer risk, therefore the availability of a database that can be searched and updated by the different teams is highly desirable [172].

**Funding** Open access funding provided by Università degli Studi di Cagliari within the CRUI-CARE Agreement.

**Data availability** Not available.

## Declarations

**Conflict of interest** None.

**Research involving human participants and/or animals** The study was conducted in compliance with ethical standards.

**Informed consent** Not applicable.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

1. Rosato L, De Crea C, Bellantone R, Brandi ML, De Toma G, Filetti S, Miccoli P, Pacini F, Pelizzo MR, Pontecorvi A, Avenia N, De Pasquale L, Chiofalo MG, Gurrado A, Innaro N, La Valle G, Lombardi CP, Marini PL, Mondini G, Mullineris B, Pezzullo L, Raffaelli M, Testini M, De Palma M (2016) Diagnostic, therapeutic and health-care management protocol in thyroid surgery: a position statement of the Italian Association of Endocrine Surgery Units (U.E.C. CLUB). *J Endocrinol Invest* 39(8):939–953. <https://doi.org/10.1007/s40618-016-0455-3>
2. Linee Guida 2022 Position Statement-Gestione del Nodulo Benigno della Tiroide causa di sintomi locali. Associazione dei Medici Endocrinologi (AME). <https://www.associazionemediciendocrinologi.it/index.php/pubblicazioni/position-statement-linee-guida>
3. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2016) 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. *Thyroid* 26(1):1–133. <https://doi.org/10.1089/thy.2015.0020>
4. Elisei R, Bottici V, Luchetti F et al (2004) Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. *J Clin Endocrinol Metab* 89:163–168
5. Rosato L, Raffaelli M, Bellantone R et al (2014) Diagnostic, therapeutic and healthcare management protocols in parathyroid surgery: II consensus conference of the Italian Association of Endocrine Surgery Units (UEC CLU). *J Endocrinol Invest* 37:149–165

6. Tessler FN, Middleton WD, Grant EG (2017) ACR thyroid imaging, reporting and data system (TI-RADS): white paper of the ACR TI-RADS Committee. *J Am Coll Radiol* 14(5):587–595
7. Castellana M, Castellana C, Treglia G et al (2020) Performance of five ultrasound risk stratification systems in selecting thyroid nodules for FN, 2020. *J Clin Endocrinol Metab* 105(5):dgz170
8. Fadda G, Basolo F, Bondi A, Bussolati G, Crescenzi A, Nappi O, Nardi F, Papotti M, Taddei G, Palombini L; SIAPEC-IAP Italian Consensus Working Group (2010) Cytological classification of thyroid nodules. Proposal of the SIAPEC-IAP Italian Consensus Working Group. *Pathologica* 102(5):405–408 (**English, Italian**)
9. Pagni F, Prada M, Goffredo P, Isimbaldi G, Crippa S, Di Bella C, Leone BE, San Gerardo Hospital collaborators group (2014) “Indeterminate for malignancy” (Tir3/Thy3 in the Italian and British systems for classification) thyroid fine needle aspiration (FNA) cytology reporting: morphological criteria and clinical impact. *Cytopathology* 25(3):170–176. <https://doi.org/10.1111/cyt.12085>
10. Sparano C, Parenti G, Cilotti A, Bencini L, Calistri M, Mannucci E, Biagini C, Vezzosi V, Mannelli M, Forti G, Petrone L (2019) Clinical impact of the new SIAPEC-IAP classification on the indeterminate category of thyroid nodules. *J Endocrinol Invest* 42(1):1–6. <https://doi.org/10.1007/s40618-018-0871-7>. (**epub 2018 Mar 15**)
11. Trimboli P, Castellana M, Virili C (2020) Performance of contrast-enhanced ultrasound (CEUS) in assessing thyroid nodules: a systematic review and meta-analysis using histological standard of reference. *Radiol Med* 125(4):406–415
12. Yeh MW, Bauer AJ, Bernet VA et al (2015) American Thyroid Association statement on preoperative imaging for thyroid cancer surgery. *Thyroid* 25:3–14
13. Magri F, Chytiris S, Chiovato L (2016) The role of elastography in thyroid ultrasonography. *Curr Opin Endocrinol Diabetes Obes.* 23(5):416–422
14. Nardi F, Basolo F, Crescenzi A et al (2014) Italian consensus for the classification and reporting of thyroid cytology. *J Endocrinol Invest* 37:593–599
15. Lombardi CP, D’Amore AM, Grani G, Ramundo V, Boscherini M, Gordini L, Marzi F, Tedesco S, Boccale R (2020) Endocrine surgery during covid-19 pandemic covid: do we need an update of indications in Italy? *Endocrine* 68(3):485–488
16. Kristensen SD et al (2014) 2014 ESC/ESA Guidelines on non cardiac-surgery; cardiovascular assessment and management. *Eur Heart J* 2014:2400–2403
17. Gould MK, Garcia DA, Wren SM, Karanicolas PJ, Arcelus JL, Heit JA, Samama CM (2012) Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 141(2 Suppl):e227S–e277S. <https://doi.org/10.1378/chest.11-2297>. Erratum in: *Chest*. 2012 May;141(5):1369.
18. Raval AN, Cigarroa JE, Chung MK, Diaz-Sandoval LJ, Diercks D, Piccini JP, Jung HS, Washam JB, Welch BG, Zazulia AR, Collins SP (2017) Management of patients on non-vitamin k antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the american heart association. *Circulation* 135(10):e604–e633. <https://doi.org/10.1161/CIR.0000000000000477>
19. Rosato L, De Toma G, Bellantone R, Avenia N, Cavallaro G, Dobrinja C, Chiofalo MG, De Crea C, De Palma M, Gasparri G, Gurrado A, Lombardi C, Miccoli P, Mullineris B, Nasi PG, Pelizzo MR, Pezzullo L, Perigli G, Testini M; Associazione delle Unità di Endocrinochirurgia Italiana (2012) Protocolli gestionali diagnostico-terapeutico-assistenziali in chirurgia tiroidea dell’s associazione delle unità di endocrinochirurgia Italiana (club delle U.E.C) [Diagnostic, therapeutic and healthcare management protocols in thyroid surgery: 3rd consensus conference of the Italian association of endocrine surgery units (U.E.C. CLUB)]. *Minerva Chir.* 67(5):365–379 (**Italian**)
20. Gentile I, Rosato L, Avenia N et al (2014) Do Italian surgeons use antibiotic prophylaxis in thyroid surgery? Results from a national study (UEC–Italian Endocrine Surgery Units Association). *Ann Ital Chir* 85:33–37
21. Gould MK, Garcia DA, Wren SM et al (2012) Prevention of VTE in nonorthopedic surgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 141:e227S–e277S
22. Delfrate R, Lampugnani R, Rosato L (2008) Complicanze da posizione sul letto operatorio e lesioni del plesso brachiale. In: Rosato L. *Trattato Italiano di Endocrinochirurgia* (ed) CLUB delle U.E.C.—Grafica Santhiatese, vol I, pp 403–404 (2008)
23. National Comprehensive Cancer Network (2021) NCCN clinical practice guidelines in oncology: thyroid carcinoma [Internet]. In: Plymouth meeting: NCCN. c2021. [http://www.nccn.org/physiassionsals/physician\\_gls/pdf/thyroid.pdf](http://www.nccn.org/physiassionsals/physician_gls/pdf/thyroid.pdf). Accessed 4 Jun 2021
24. Chen AY, Bernet VJ, Carty SE, Davies TF, Ganly I, Inabnet WB 3rd, Shaha AR; Surgical Affairs Committee of the American Thyroid Association (2014) American Thyroid Association statement on optimal surgical management of goiter. *Thyroid* 24(2):181–189. <https://doi.org/10.1089/thy.2013.0291> (**epub 2014 Jan 20**)
25. Filetti S, Durante C, Hartl D, Leboulleux S, Locati LD, Newbold K, Papotti MG, Berruti A; ESMO Guidelines Committee (2019) Electronic address: [clinicalguidelines@esmo.org](mailto:clinicalguidelines@esmo.org). Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 30(12):1856–1883. <https://doi.org/10.1093/annonc/mdz400>
26. Vasileiou M, Gilbert J, Fishburn S, Boelaert K; Guideline Committee (2020) Thyroid disease assessment and management: summary of NICE guidance. *BMJ* 368:m41. <https://doi.org/10.1136/bmj.m41> (**erratum in: BMJ. 2020;368:m437**)
27. Pacini F, Basolo F, Bellantone R, Boni G, Cannizzaro MA, De Palma M, Durante C, Elisei R, Fadda G, Frasoldati A, Fugazzola L, Guglielmi R, Lombardi CP, Miccoli P, Papini E, Pellegritti G, Pezzullo L, Pontecorvi A, Salvatori M, Seregini E, Vitti P (2018) Italian consensus on diagnosis and treatment of differentiated thyroid cancer: joint statements of six Italian societies. *J Endocrinol Invest* 41(7):849–876. <https://doi.org/10.1007/s40618-018-0884-2>. (**epub 2018 May 4**)
28. Bellantone R, Boscherini M, Lombardi CP, Bossola M, Rubino F, De Crea C, Alesina P, Traini E, Cozza T, D’alatri L (2001) Is the identification of the external branch of the superior laryngeal nerve mandatory in thyroid operation? Results of a prospective randomized study. *Surgery* 130(6):1055–1059. <https://doi.org/10.1067/msy.2001.118375>
29. Barczyński M, Randolph GW, Cernea CR, Dralle H, Dionigi G, Alesina PF, Mihai R, Finck C, Lombardi D, Hartl DM, Miyauchi A, Serpell J, Snyder S, Volpi E, Woodson G, Kraimps JL, Hisham AN; International Neural Monitoring Study Group (2013) External branch of the superior laryngeal nerve monitoring during thyroid and parathyroid surgery: International Neural Monitoring Study Group standards guideline statement. *Laryngoscope* 123 (Suppl 4):S1–S14. <https://doi.org/10.1002/lary.24301>
30. Del Rio P, Bonati E, Loderer T, Rossini M, Cozzani F (2021) Can we routinely identify the external branch of the superior laryngeal nerves with neural monitoring?: a prospective report on 176 consecutive nerves at risk. *Updates Surg.* 73(6):2275–2281. <https://doi.org/10.1007/s13304-021-01084-6> (**epub 2021 May 26**)

31. Linos D (2011) Minimally invasive thyroidectomy: a comprehensive appraisal of existing techniques. *Surgery* 150(1):17–24. <https://doi.org/10.1016/j.surg.2011.02.018>. (epub 2011 May 18)
32. Tae K (2021) Robotic thyroid surgery. *Auris Nasus Larynx* 48(3):331–338. <https://doi.org/10.1016/j.anl.2020.06.007>. (epub 2020 Jul 4)
33. Slotema ET, Sebag F, Henry JF (2008) What is the evidence for endoscopic thyroidectomy in the management of benign thyroid disease? *World J Surg* 32(7):1325–1332. <https://doi.org/10.1007/s00268-008-9505-0>
34. Bellantone R, Lombardi C, Raffaelli M (2004) Tiroidectomia video-assistita. *Enciclopédie Médico-Chirurgicale—Tecnique Chirurgiche—Chirurgia Generale*, I–46–460-A. Elsevier SAS, Paris, pp 1–14
35. Miccoli P, Berti P, Raffaelli M, Conte M, Materazzi G, Galleri D (2001) Minimally invasive video-assisted thyroidectomy. *Am J Surg* 181(6):567–570. [https://doi.org/10.1016/s0002-9610\(01\)00625-0](https://doi.org/10.1016/s0002-9610(01)00625-0)
36. Del Rio P, Viani L, Montana CM, Cozzani F, Sianesi M (2016) Minimally invasive thyroidectomy: a ten years experience. *Gland Surg* 5(3):295–299. <https://doi.org/10.21037/gs.2016.01.04>
37. Lombardi CP, Raffaelli M, D'alatri L, De Crea C, Marchese MR, Maccora D, Paludetti G, Bellantone R (2008) Video-assisted thyroidectomy significantly reduces the risk of early postthyroidectomy voice and swallowing symptoms. *World J Surg* 32(5):693–700. <https://doi.org/10.1007/s00268-007-9443-2>
38. Miccoli P, Minuto MN, Ugolini C, Pisano R, Fosso A, Berti P (2008) Minimally invasive video-assisted thyroidectomy for benign thyroid disease: an evidence-based review. *World J Surg* 32(7):1333–1340. <https://doi.org/10.1007/s00268-008-9479-y>
39. Lombardi CP, Carnassale G, D'Amore A, Milano V, De Crea C, Raffaelli M, Bellantone R (2017) Morbidity from minimally invasive video-assisted thyroidectomy: a general review. *Gland Surg* 6(5):488–491. <https://doi.org/10.21037/gs.2017.06.05>
40. Scerrino G, Melfa G, Raspanti C, Rotolo G, Salamone G, Licari L, Fontana T, Tutino R, Porrello C, Gulotta G, Cocorullo G (2019) Minimally invasive video-assisted thyroidectomy: analysis of complications from a systematic review. *Surg Innov* 26(3):381–387. <https://doi.org/10.1177/1553350618823425>. (epub 2019 Jan 11)
41. Dionigi G, Dralle H, Materazzi G, Kim HY, Miccoli P (2020) Happy 20th birthday to minimally invasive video-assisted thyroidectomy! *J Endocrinol Invest* 43(3):385–388. <https://doi.org/10.1007/s40618-019-01119-1>. (epub 2019 Sep 25)
42. Lombardi CP, Raffaelli M, De Crea C, Princi P, Castaldi P, Spaventa A, Salvatori M, Bellantone R (2007) Report on 8 years of experience with video-assisted thyroidectomy for papillary thyroid carcinoma. *Surgery* 142(6):944–951. <https://doi.org/10.1016/j.surg.2007.09.022>. (discussion 944–951)
43. Lombardi CP, Raffaelli M, De Crea C, Sessa L, Rampulla V, Bellantone R (2012) Video-assisted versus conventional total thyroidectomy and central compartment neck dissection for papillary thyroid carcinoma. *World J Surg* 36(6):1225–1230. <https://doi.org/10.1007/s00268-012-1439-x>
44. Miccoli P, Pinchera A, Materazzi G, Biagini A, Berti P, Faviana P, Molinaro E, Viola D, Elisei R (2009) Surgical treatment of low- and intermediate-risk papillary thyroid cancer with minimally invasive video-assisted thyroidectomy. *J Clin Endocrinol Metab* 94(5):1618–1622. <https://doi.org/10.1210/jc.2008-1418>. (epub 2009 Feb 17)
45. Zhang D, Caruso E, Sun H, Anuwong A, Tufano R, Materazzi G, Dionigi G, Kim HY (2019) Classifying pain in transoral endoscopic thyroidectomy. *J Endocrinol Invest* 42(11):1345–1351. <https://doi.org/10.1007/s40618-019-01071-0>. (epub 2019 Jun 11)
46. Akritidou E, Douridas G, Spartalis E, Tsourouffis G, Dimitroulis D, Nikiteas NI (2022) Complications of trans-oral endoscopic thyroidectomy vestibular approach: a systematic review. *In Vivo* 36(1):1–12. <https://doi.org/10.21873/invivo.12671>
47. Lee J, Kang SW, Jung JJ, Choi UJ, Yun JH, Nam KH, Soh EY, Chung WY (2011) Multicenter study of robotic thyroidectomy: short-term postoperative outcomes and surgeon ergonomic considerations. *Ann Surg Oncol* 18(9):2538–2547. <https://doi.org/10.1245/s10434-011-1628-0>. (epub 2011 Mar 4)
48. Richmon JD, Pattani KM, Benhidjeb T, Tufano RP (2011) Transoral robotic-assisted thyroidectomy: a preclinical feasibility study in 2 cadavers. *Head Neck* 33(3):330–333. <https://doi.org/10.1002/hed.21454>
49. Terris DJ, Singer MC, Seybt MW (2011) Robotic facelift thyroidectomy: patient selection and technical considerations. *Surg Laparosc Endosc Percutan Tech* 21(4):237–242. <https://doi.org/10.1097/SLE.0b013e3182266dd6>
50. Lee KE, Koo do H, Im HJ, Park SK, Choi JY, Paeng JC, Chung JK, Oh SK, Youn YK (2011) Surgical completeness of bilateral axillo-breast approach robotic thyroidectomy: comparison with conventional open thyroidectomy after propensity score matching. *Surgery* 150(6):1266–1274. <https://doi.org/10.1016/j.surg.2011.09.015>
51. Piccoli M, Mullineris B, Gozzo D et al (2015) Trans-axillary thyroidectomy and parathyroidectomy. In: Spinoglio G (ed) *Robotic surgery—current application and new trends*. Springer, New York, pp 15–22
52. Piccoli M, Mullineris B, Gozzo D, Colli G, Pecchini F, Nigro C, Rochira V (2019) Evolution strategies in transaxillary robotic thyroidectomy: considerations on the first 449 cases performed. *J Laparoendosc Adv Surg Tech A*. 29(4):433–440. <https://doi.org/10.1089/lap.2019.0021>. (epub 2019 Mar 21)
53. Fregoli L, Rossi L, Papini P, Materazzi G (2020) Robotic transaxillary thyroidectomy: state of the art. *Gland Surg* 9(Suppl 1):S61–S64. <https://doi.org/10.21037/gs.2019.10.11>
54. D'Ajello F, Cirocchi R, Docimo G, Catania A, Ardito G, Rosato L, Avenia N (2010) Thyroidectomy with ultrasonic dissector: a multicentric experience. *Il Giornale di chirurgia* 31(6–7):289–292
55. D'Ajello F, Cirocchi R, Docimo G, Catania A, Ardito G, Rosato L, Avenia N (2020) Thyroidectomy with ultrasonic dissector: a multicentric experience. *Cytopathology* 128(2):107–118
56. Lombardi CP, Raffaelli M, De Crea C, Traini E, Oragano L, Sol-lazzi L, Bellantone R (2007) Complicanze in chirurgia tiroidea [Complications in thyroid surgery]. *Minerva Chir* 62(5):395–408 (Italian)
57. Rosato L, Avenia N, Bernante P, De Palma M, Gulino G, Nasi PG, Pelizzo MR, Pezzullo L (2004) Complications of thyroid surgery: analysis of a multicentric study on 14,934 patients operated on in Italy over 5 years. *World J Surg* 28(3):271–276. <https://doi.org/10.1007/s00268-003-6903-1>. (epub 2004 Feb 17)
58. Gambardella C, Polistena A, Sanguinetti A, Patrone R, Napolitano S, Esposito D, Testa D, Marotta V, Faggiano A, Calò PG, Avenia N, Conzo G (2017) Unintentional recurrent laryngeal nerve injuries following thyroidectomy: is it the surgeon who pays the bill? *Int J Surg* 41(Suppl 1):S55–S59. <https://doi.org/10.1016/j.ijsu.2017.01.112>
59. Polistena A, Monacelli M, Lucchini R, Triola R, Conti C, Avenia S, Barillaro I, Sanguinetti A, Avenia N (2015) Surgical morbidity of cervical lymphadenectomy for thyroid cancer: a retrospective cohort study over 25 years. *Int J Surg* 21:128–134. <https://doi.org/10.1016/j.ijsu.2015.07.698>. (epub 2015 Aug 5)
60. Bergenfelz A, Jansson S, Kristoffersson A, Mårtensson H, Reihner E, Wallin G, Lausen I (2008) Complications to thyroid surgery: results as reported in a database from a multicenter audit comprising 3,660 patients. *Langenbecks Arch Surg*

- 393(5):667–673. <https://doi.org/10.1007/s00423-008-0366-7>. (epub 2008 Jul 17)
61. Woodson G (2003) Pathophysiology of recurrent laryngeal nerve. In: Randolph GW (ed) *Surgery of the thyroid and parathyroid glands*. Saunders, Philadelphia, pp 366–373
  62. Liddy W, Wu CW, Dionigi G, Donatini G, Giles Senyurek Y, Kamani D, Iwata A, Wang B, Okose O, Cheung A, Saito Y, Casella C, Aygun N, Uludag M, Brauckhoff K, Carnaille B, Tunca F, Barczyński M, Kim HY, Favero E, Innaro N, Vamvakidis K, Serpell J, Romanchishen AF, Takami H, Chiang FY, Schneider R, Dralle H, Shin JJ, Abdelhamid Ahmed AH, Randolph GW (2021) Varied recurrent laryngeal nerve course is associated with increased risk of nerve dysfunction during thyroidectomy: results of the surgical anatomy of the recurrent laryngeal nerve in thyroid surgery study, an International Multicenter Prospective Anatomic and Electrophysiologic Study of 1000 monitored nerves at risk from the International Neural Monitoring Study Group. *Thyroid* 31(11):1730–1740. <https://doi.org/10.1089/thy.2021.0155>
  63. Randolph GW, Dralle H, Abdullah H, Barczynski M, Bellantone R, Brauckhoff M, Carnaille B, Cherenko S, Chiang FY, Dionigi G, Finck C, Hartl D, Kamani D, Lorenz K, Miccolli P, Mihai R, Miyauchi A, Orloff L, Perrier N, Poveda MD, Romanchishen A, Serpell J, Sitges-Serra A, Sloan T, Van Slycke S, Snyder S, Takami H, Volpi E, Woodson G, International Intraoperative Monitoring Study Group (2011) Electrophysiologic recurrent laryngeal nerve monitoring during thyroid and parathyroid surgery: international standards guideline statement. *Laryngoscope* 121(Suppl 1):S1–S16. <https://doi.org/10.1002/lary.21119>
  64. Calò PG, Medas F, Conzo G, Podda F, Canu GL, Gambardella C, Pisano G, Erdas E, Nicolosi A (2017) Intraoperative neuromonitoring in thyroid surgery: is the two-staged thyroidectomy justified? *Int J Surg* 41(Suppl 1):S13–S20. <https://doi.org/10.1016/j.ijss.2017.02.001>
  65. Del Rio P, Cozzani F, Rossini M, Loderer T, Bignami E, Bonati E (2021) Mini-invasive thyroidectomy and intraoperative neuromonitoring: a high-volume single-center experience in 215 consecutive cases. *Minerva Surg* 76(2):160–164. <https://doi.org/10.23736/S2724-5691.20.08339-X>. (epub 2020 May 26)
  66. Wu CW, Huang TY, Randolph GW, Barczyński M, Schneider R, Chiang FY, Silver Karcioğlu A, Wojtczak B, Frattini F, Gualniera P, Sun H, Weber F, Angelos P, Dralle H, Dionigi G (2021) Informed consent for intraoperative neural monitoring in thyroid and parathyroid surgery—consensus statement of the International Neural Monitoring Study Group. *Front Endocrinol (Lausanne)*. 7(12):795281. <https://doi.org/10.3389/fendo.2021.795281>
  67. Sinclair CF, Buczek E, Cottril E, Angelos P, Barczynski M, Ho AS, Makarin V, Musholt T, Scharpf J, Schneider R, Stack BC Jr, Tellez MJ, Tolley N, Woodson G, Wu CW, Randolph G (2022) Clarifying optimal outcome measures in intermittent and continuous laryngeal neuromonitoring. *Head Neck* 44(2):460–471. <https://doi.org/10.1002/hed.26946>. (epub 2021 Dec 1)
  68. Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, Rivkees SA, Samuels M, Sosa JA, Stan MN, Walter MA (2016) 2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. *Thyroid* 26(10):1343–1421. <https://doi.org/10.1089/thy.2016.0229>. (erratum in: *Thyroid*. 2017;27(11):1462)
  69. Akram S, Elfenbein DM, Chen H, Schneider DF, Sippel RS (2020) Assessing American Thyroid Association guidelines for total thyroidectomy in Graves' disease. *J Surg Res* 245:64–71. <https://doi.org/10.1016/j.jss.2019.07.029>. (epub 2019 Aug)
  70. Liu ZW, Masterson L, Fish B, Jani P, Chatterjee K (2015) Thyroid surgery for Graves' disease and Graves' ophthalmopathy. *Cochrane Database Syst Rev* 25(11):CD010576. <https://doi.org/10.1002/14651858.CD010576.pub2>
  71. Cibas ES, Ali SZ (2017) The 2017 Bethesda system for reporting thyroid cytopathology. *Thyroid* 27(11):1341–1346. <https://doi.org/10.1089/thy.2017.0500>
  72. Polistena A, Sanguinetti A, Lucchini R, Avenia S, Galasse S, Farabi R, Monacelli M, Avenia N (2019) Follicular proliferation TIR3B: the role of total thyroidectomy vs lobectomy. *BMC Surg* 18(Suppl 1):22. <https://doi.org/10.1186/s12893-019-0485-9>
  73. Raffaelli M, De Crea C, Ronti S, Bellantone R, Lombardi CP (2011) Substernal goiters: incidence, surgical approach, and complications in a tertiary care referral center. *Head Neck* 33(10):1420–1425. <https://doi.org/10.1002/hed.21617>. (epub 2010 Nov 10)
  74. Testini M, Gurrado A, Avenia N, Bellantone R, Biondi A, Brazzarola P, Calzolari F, Cavallaro G, De Toma G, Guida P, Lissidini G, Loizzi M, Lombardi CP, Piccinni G, Portincasa P, Rosato L, Sartori N, Zugni C, Basile F (2011) Does mediastinal extension of the goiter increase morbidity of total thyroidectomy? A multicenter study of 19,662 patients. *Ann Surg Oncol* 18(8):2251–2259. <https://doi.org/10.1245/s10434-011-1596-4>. (epub 2011 Feb 19)
  75. White ML, Doherty GM, Gauger PG (2008) Evidence-based surgical management of substernal goiter. *World J Surg* 32(7):1285–1300. <https://doi.org/10.1007/s00268-008-9466-3>
  76. Polistena A, Sanguinetti A, Lucchini R, Galasse S, Monacelli M, Avenia S, Triola R, Bugiantella W, Rondelli F, Cirocchi R, Avenia N (2016) Surgical approach to mediastinal goiter: an update based on a retrospective cohort study. *Int J Surg* 28(Suppl 1):S42–S46. <https://doi.org/10.1016/j.ijss.2015.12.058>. (epub 2015 Dec 18)
  77. Pacini F (2015) Observation for newly diagnosed micro-papillary thyroid cancer: is now the time? *J Endocrinol Invest* 38(1):101–102. <https://doi.org/10.1007/s40618-014-0200-8>. (epub 2014 Oct 26)
  78. Dobrinja C, Samardzic N, Giudici F, Raffaelli M, De Crea C, Sessa L, Docimo G, Ansaldo GL, Minuto M, Varaldo E, Dionigi G, Spiezia S, Boniardi M, Pauna I, De Pasquale L, Testini M, Gurrado A, Pasculli A, Pezzolla A, Lattarulo S, Calò PG, Graceffa G, Massara A, Docimo L, Ruggiero R, Parmeggiani D, Iacobone M, Innaro N, Lombardi CP, de Manzini N (2021) Hemithyroidectomy versus total thyroidectomy in the intermediate-risk differentiated thyroid cancer: the Italian Societies of Endocrine Surgeons and Surgical Oncology Multicentric Study. *Updates Surg*. 73(5):1909–1921. <https://doi.org/10.1007/s13304-021-01140-1>. (epub 2021 Aug 25)
  79. Gulec SA, Ahuja S, Avram AM, Bernet VJ, Bourguet P, Draganesu C, Elisei R, Giovanella L, Grant F, Greenspan B, Hegedüs L, Jonklaas J, Kloos RT, Luster M, Oyen WJG, Smit J, Tuttle RM (2021) A joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer. *Thyroid* 31(7):1009–1019. <https://doi.org/10.1089/thy.2020.0826>. (epub 2021 Jun 23)
  80. Zambeli-Ljepović A, Wang F, Dinan MA, Hyslop T, Stang MT, Roman SA, Sosa JA, Scheri RP (2019) Extent of surgery for low-risk thyroid cancer in the elderly: equipoise in survival but not in short-term outcomes. *Surgery* 166(5):895–900. <https://doi.org/10.1016/j.surg.2019.05.035>. (epub 2019 Jul 6)
  81. Sugitani I, Ito Y, Takeuchi D, Nakayama H, Masaki C, Shindo H, Teshima M, Horiguchi K, Yoshida Y, Kanai T, Hirokawa M, Hames KY, Tabei I, Miyauchi A (2021) Indications and strategy for active surveillance of adult low-risk papillary thyroid microcarcinoma: consensus statements from the Japan Association

- of Endocrine Surgery Task Force on management for papillary thyroid microcarcinoma. *Thyroid* 31(2):183–192. <https://doi.org/10.1089/thy.2020.0330>. (epub 2020 Nov 2)
82. Molinaro E, Campopiano MC, Elisei R (2021) Management of endocrine disease: papillary thyroid microcarcinoma: toward an active surveillance strategy. *Eur J Endocrinol* 185(1):R23–R34. <https://doi.org/10.1530/EJE-21-0256>
  83. Patrone R, Velotti N, Masone S, Conzo A, Flagiello L, Cacciatore C, Filardo M, Granata V, Izzo F, Testa D, Avenia S, Sanguinetti A, Polistena A, Conzo G (2021) Management of low-risk thyroid cancers: is active surveillance a valid option? A systematic review of the literature. *J Clin Med* 10(16):3569. <https://doi.org/10.3390/jcm10163569>
  84. Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal MS, Santoro M, Schlumberger M, Shah M, Waguespack SG, American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma (2015) Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. *Thyroid* 25(6):567–610. <https://doi.org/10.1089/thy.2014.0335>
  85. Bible KC, Kebebew E, Brierley J, Brito JP, Cabanillas ME, Clark TJ Jr, Di Cristofano A, Foote R, Giordano T, Kasperbauer J, Newbold K, Nikiforov YE, Randolph G, Rosenthal MS, Sawka AM, Shah M, Shaha A, Smallridge R, Wong-Clark CK (2021) 2021 American Thyroid Association Guidelines for management of patients with anaplastic thyroid cancer. *Thyroid* 31(3):337–386. <https://doi.org/10.1089/thy.2020.0944>. (erratum in: **Thyroid**. 2021;31(10):1606–1607)
  86. Papini E, Monpeyssen H, Frasoldati A, Hegedüs L (2020) 2020 European Thyroid Association Clinical Practice Guideline for the use of image-guided ablation in benign thyroid nodules. *Eur Thyroid J* 9(4):172–185. <https://doi.org/10.1159/000508484>. (epub 2020 Jun 8)
  87. Papini E, Pacella CM, Solbiati LA, Achille G, Barbaro D, Bernardi S, Cantisani V, Cesareo R, Chiti A, Cozzaglio L, Crescenzi A, De Cobelli F, Deandrea M, Fugazzola L, Gambelunghe G, Garberoglio R, Giugliano G, Luzzi L, Negro R, Persani L, Raggiunti B, Sardanelli F, Seregni E, Sollini M, Spiezia S, Stacul F, Van Doorne D, Sconfienza LM, Mauri G (2019) Minimally-invasive treatments for benign thyroid nodules: a Delphi-based consensus statement from the Italian minimally-invasive treatments of the thyroid (MITT) group. *Int J Hyperthermia* 36(1):376–382. <https://doi.org/10.1080/02656736.2019.1575482>. (epub 2019 Mar 26)
  88. Gharib H, Papini E (2007) Thyroid nodules: clinical importance, assessment, and treatment. *Endocrinol Metab Clin N Am* 36:707–735
  89. Hegedus L, Bonnema SJ, Bennedbaek FN (2003) Management of simple nodular goiter: current status and future perspectives. *Endocr Rev* 24:102–132
  90. Papini E et al (2016) Laser, radiofrequency, and ethanol ablation for the management of thyroid nodules. *Curr Opin Endocrinol Diabetes Obes*. <https://doi.org/10.1097/MED.0000000000000282>
  91. Jung SL et al (2018) Efficacy and safety of radiofrequency ablation for benign thyroid nodules: a prospective multicenter study. *Korean J Radiol*. <https://doi.org/10.1530/EJE-18-0685>
  92. Ji Hong M et al (2015) Radiofrequency ablation is a thyroid function-preserving treatment for patients with bilateral benign thyroid nodules. *J Vasc Interv Radiol*. <https://doi.org/10.1016/j.jvir.2014.09.015>
  93. Deandrea M et al (2019) Long-term efficacy of a single session of RFA for benign thyroid nodules: a longitudinal 5-year observational study. *J Clin Endocrinol Metab*. <https://doi.org/10.1210/jc.2018-02808>
  94. Feldkamp J et al (2020) Non-surgical and non-radioiodine techniques for ablation of benign thyroid nodules: consensus statement and recommendation. *Exp Clin Endocrinol Diabetes*. <https://doi.org/10.1055/a-1075-2025>
  95. Mauri G, Bernardi S, Palermo A, Cesareo R, Italian Minimally-Invasive Treatments of the Thyroid group (2022) Minimally-invasive treatments for benign thyroid nodules: recommendations for information to patients and referring physicians by the Italian Minimally-Invasive Treatments of the Thyroid group. *Endocrine*. <https://doi.org/10.1007/s12020-022-03005-y>
  96. Mauri G, Papini E, Bernardi S, Barbaro D, Cesareo R, De Feo P, Deandrea M, Fugazzola L, Gambelunghe G, Greco G, Messina C, Monti S, Mormile A, Negro R, Offi C, Palermo A, Persani L, Presciuttini F, Solbiati LA, Spiezia S, Stacul F, Viganò M, Sconfienza LM. Image-guided thermal ablation in autonomously functioning thyroid nodules. A retrospective multicenter three-year follow-up study from the Italian Minimally Invasive Treatment of the Thyroid (MITT) Group
  97. Kim JH, Baek JH, Lim HK, Ahn HS, Baek SM, Choi YJ et al (2017) Guideline Committee for the Korean Society of Thyroid Radiology (KSThR) and Korean Society of Radiology. Thyroid radiofrequency ablation guideline. *Korean Society of Thyroid Radiology, Seoul*
  98. Hegedüs L, Bonnema SJ (2010) Approach to management of the patient with primary or secondary intrathoracic goiter. *J Clin Endocrinol Metab* 95(12):5155–5162
  99. Yan L, Zhang M, Song Q, Xie F, Luo Y (2022) Clinical outcomes of radiofrequency ablation for multifocal papillary thyroid microcarcinoma versus unifocal papillary thyroid microcarcinoma: a propensity-matched cohort study. *Eur Radiol* 32(2):1216–1226. <https://doi.org/10.1007/s00330-021-08133-z>. (epub 2021 Aug 6)
  100. Zhang C, Yin J, Hu C, Ye Q, Wang P, Huang P (2022) Comparison of ultrasound guided percutaneous radiofrequency ablation and open thyroidectomy in the treatment of low-risk papillary thyroid microcarcinoma: a propensity score matching study. *Clin Hemorheol Microcirc* 80(2):73–81. <https://doi.org/10.3233/CH-201087>
  101. Stan MN, Papaleontiou M, Schmitz JJ, Castro MR (2021) Non-surgical management of thyroid nodules - the role of ablative therapies. *J Clin Endocrinol Metab*. 25:dgab917. <https://doi.org/10.1210/clinem/dgab917>
  102. Yan L, Zhang M, Song Q, Luo Y (2021) Ultrasound-guided radiofrequency ablation versus thyroid lobectomy for low-risk papillary thyroid microcarcinoma: a propensity-matched cohort study of 884 patients. *Thyroid* 31(11):1662–1672. <https://doi.org/10.1089/thy.2021.0100>. (epub 2021 Sep 17)
  103. Lim LS, Lin WC, Chiang PL, Huang SC, Chen YS, Chang YH, Chen WC, Chi SY, Chou CK (2021) One year follow-up of US-guided radiofrequency ablation for low-risk papillary thyroid microcarcinoma: the first experience in Taiwan. *J Formos Med Assoc* S0929–6646(21):00472–00481. <https://doi.org/10.1016/j.jfma.2021.09.026>. Online ahead
  104. Offi C, Misso C, Antonelli G, Esposito MG, Brancaccio U, Spiezia S (2021) Laser ablation treatment of recurrent lymph node metastases from papillary thyroid carcinoma. *J Clin Med* 10(22):5295. <https://doi.org/10.3390/jcm10225295>
  105. Lu G, Chen L (2022) Cervical lymph node metastases in papillary thyroid cancer: preoperative staging with ultrasound and/or computed tomography. *Medicine (Baltimore)* 101(9):e28909. <https://doi.org/10.1097/MD.00000000000028909>
  106. Randle RW, Pitt SC (2021) The role of node dissection for thyroid cancer. *Adv Surg* 55:131–145. <https://doi.org/10.1016/j.yasu.2021.05.010>. (epub 2021 Jul 6)
  107. Dy BM, Shaha AR (2018) Philosophy on neck dissection in thyroid cancer-current controversies and consensus. *Indian J Surg*

- Oncol 9(1):2–5. <https://doi.org/10.1007/s13193-017-0720-8>. (epub 2017 Dec 21)
108. Mazzaferri EL, Doherty GM, Steward DL (2009) The pros and cons of prophylactic central compartment lymph node dissection for papillary thyroid carcinoma. *Thyroid* 19(7):683–689. <https://doi.org/10.1089/thy.2009.1578>
  109. Alvarado R, Sywak MS, Delbridge L, Sidhu SB (2009) Central lymph node dissection as a secondary procedure for papillary thyroid cancer: is there added morbidity? *Surgery* 145(5):514–518
  110. Kim H, Kim TH, Choe JH, Kim JH, Kim JS, Oh YL, Hahn SY, Shin JH, Chi S, Jung SH, Kim YN, Kim HI, Kim SW, Chung JH (2017) Patterns of initial recurrence in completely resected papillary thyroid carcinoma. *Thyroid* 27(7):908–914. <https://doi.org/10.1089/thy.2016.0648>
  111. Nixon IJ, Wang LY, Ganly I, Patel SG, Morris LG, Migliacci JC, Tuttle RM, Shah JP, Shaha AR (2016) Outcomes for patients with papillary thyroid cancer who do not undergo prophylactic central neck dissection. *Br J Surg* 103(3):218–225. <https://doi.org/10.1002/bjs.10036>
  112. Vural A, Çağlı S, Yüce I, Kokoglu K, Gündoğdu R (2018) Does central lymph node dissection in patients with papillary thyroid carcinoma increase morbidity rates? A comparative study. *Gülhane Tıp Dergisi* 60:51
  113. Viola D, Materazzi G, Valerio L, Molinaro E, Agate L, Faviana P et al (2015) Prophylactic central compartment lymph node dissection in papillary thyroid carcinoma: clinical implications derived from the first prospective randomized controlled single institution study. *J Clin Endocrinol Metab* 100(4):1316–1324. <https://doi.org/10.1210/jc.2014-3825>
  114. Calò PG, Lombardi CP, Podda F, Sessa L, Santini L, Conzo G (2017) Role of prophylactic central neck dissection in clinically node-negative differentiated thyroid cancer: assessment of the risk of regional recurrence. *Updates Surg* 69(2):241–248. <https://doi.org/10.1007/s13304-017-0438-8>. (epub 2017 Apr 13)
  115. Sancho JJ, Lennard TW, Paunovic I, Triponez F, Sitges-Serra A (2014) Prophylactic central neck dissection in papillary thyroid cancer: a consensus report of the European Society of Endocrine Surgeons (ESES). *Langenbecks Arch Surg* 399(2):155–163
  116. Raffaelli M, De Crea C, Sessa L, Fadda G, Bellantone C, Lombardi CP (2015) Ipsilateral central neck dissection plus frozen section examination versus prophylactic bilateral central neck dissection in cN0 papillary thyroid carcinoma. *Ann Surg Oncol* 22:2302–2308
  117. Alsubaie KM, Alsubaie HM, Alzahrani FR, Alessa MA, Abdulmonem SK, Merdad MA, Al-Khatib T, Marzouki HZ, Algarni MA, Alherabi AZ (2021) Prophylactic central neck dissection for clinically node-negative papillary thyroid carcinoma. *Laryngoscope*. <https://doi.org/10.1002/lary.29912>. (epub ahead of print)
  118. Dy BM et al (2018) Philosophy on neck dissection in thyroid cancer—current controversies and consensus. *Indian J Surg Oncol* 9(1):2–5
  119. Wang Y, Nie F, Wang G, Liu T, Dong T, Sun Y (2021) Value of combining clinical factors, conventional ultrasound, and contrast-enhanced ultrasound features in preoperative prediction of central lymph node metastases of different sized papillary thyroid carcinomas. *Cancer Manag Res* 13:3403. <https://doi.org/10.2147/CMAR.S299157>
  120. Jiang L-H, Yin K-X, Wen Q-L, Chen C, Ge M-H, Tan Z (2020) Predictive risk-scoring model for central lymph node metastasis and predictors of recurrence in papillary thyroid carcinoma. *Sci Rep* 10(1):1–9. <https://doi.org/10.1038/s41598-019-55991-1>
  121. Sun W, Lan X, Zhang H, Dong W, Wang Z, He L et al (2015) Risk factors for central lymph node metastasis in CN0 papillary thyroid carcinoma: a systematic review and meta-analysis. *PLoS ONE* 10(10):e0139021. <https://doi.org/10.1371/journal.pone.0139021>
  122. Tang AL, Reid LM, Randolph GW, Steward DL (2021) 38—Central neck dissection: indications and technique. In: Randolph GW (ed) *Surgery of the thyroid and parathyroid glands*, 3rd ed. Elsevier, London, pp 372–378.e1. ISBN 9780323661270. <https://doi.org/10.1016/B978-0-323-66127-0.00038-7>
  123. Carty SE, Cooper DS, Doherty GM et al (2009) Consensus statement on the terminology and classification of central neck dissection for thyroid cancer. *Thyroid* 19:1153–1158
  124. Robbins KT, Shaha AR, Medina JE, Califano JA, Wolf GT, Ferlito A, Som PM, Day TA (2008) Consensus statement on the classification and terminology of neck dissection: Committee for Neck Dissection Classification, American Head and Neck Society. *Arch Otolaryngol Head Neck Surg* 134:536–538
  125. Agrawal N, Evasovich MR, Kandil E, Noureldine SI, Felger EA, Tufano RP et al (2017) Indications and extent of central neck dissection for papillary thyroid cancer: an American Head and Neck Society Consensus Statement. *Head Neck* 39:1269–1279
  126. Eskander A, Merdad M, Freeman JL, Witterick IJ (2013) Pattern of spread to the lateral neck in metastatic well-differentiated thyroid cancer: a systematic review and meta-analysis. *Thyroid* 23(5):583–592. <https://doi.org/10.1089/thy.2012.0493>. (epub 2013 Apr 18)
  127. Park JH, Lee YS, Kim BW, Chang HS, Park CS (2012) Skip lateral neck node metastases in papillary thyroid carcinoma. *World J Surg* 36:743–747
  128. Randolph GW, Duh QY, Heller KS, LiVolsi VA, Mandel SJ, Steward DL, Tufano RP, Tuttle RM, American Thyroid Association Surgical Affairs Committee’s Taskforce on Thyroid Cancer Nodal Surgery (2012) The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. *Thyroid* 22(11):1144–1152. <https://doi.org/10.1089/thy.2012.0043>. (epub 2012 Oct 19)
  129. Mulla MG, Knoefel WT, Gilbert J et al (2012) Lateral cervical lymph node metastases in papillary thyroid cancer: a systematic review of imaging-guided and prophylactic removal of the lateral compartment. *Clin Endocrinol (Oxf)* 77:126–131
  130. Stack BC Jr, Ferris RL, Goldenberg D, Haymart M, Shaha A, Sheth S, Sosa JA, Tufano RP, American Thyroid Association Surgical Affairs Committee (2012) American Thyroid Association consensus review and statement regarding the anatomy, terminology, and rationale for lateral neck dissection in differentiated thyroid cancer. *Thyroid* 22(5):501–508. <https://doi.org/10.1089/thy.2011.0312>. (epub 2012 Mar 21)
  131. Patel KN, Yip L, Lubitz CC, Grubbs EG, Miller BS, Shen W, Angelos P, Chen H, Doherty GM, Fahey TJ 3rd, Kebebew E, Livolsi VA, Perrier ND, Sipos JA, Sosa JA, Steward D, Tufano RP, McHenry CR, Carty SE (2020) The American Association of Endocrine Surgeons Guidelines for the definitive surgical management of thyroid disease in adults. *Ann Surg* 271(3):e21–e93. <https://doi.org/10.1097/SLA.0000000000003580>
  132. Won HR, Chang JW, Kang YE, Kang JY, Koo BS (2018) Optimal extent of lateral neck dissection for well-differentiated thyroid carcinoma with metastatic lateral neck lymph nodes: a systematic review and meta-analysis. *Oral Oncol* 87:117–125. <https://doi.org/10.1016/j.oraloncology.2018.10.035>. (epub 2018 Nov 1)
  133. Elisei R, Alevizaki M, Conte-Devolx B et al (2013) 2012 European Thyroid Association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer. *Eur Thyroid J* 1:216–231
  134. Gambardella C, Offi C, Patrone R, Conzo G, Clarizia G, Mauriello C, Tartaglia E, Di Capua F, Di Martino S, Romano RM, Fiore L, Conzo A, Docimo G (2019) Calcitonin negative

- medullary thyroid carcinoma: a challenging diagnosis or a medical dilemma? *BMC Endocr Disord* 19:45
135. Machens A, Hauptmann S, Dralle H (2008) Prediction of lateral lymph node metastases in medullary thyroid cancer. *Br J Surg* 95:586e591
  136. Machens A, Dralle H (2010) Biomarker-based risk stratification for previously untreated medullary thyroid cancer. *J Clin Endocrinol Metab.* 95:2655e2663
  137. Shaha AR (2022) Management of lateral neck nodes in common and aggressive variants of thyroid cancer. *Curr Opin Otolaryngol Head Neck Surg* 30(2):130–136. <https://doi.org/10.1097/MOO.0000000000000790>
  138. Doran HE, Wiseman SM, Palazzo FF, Chadwick D, Aspinall S (2021) Postthyroidectomy bleeding: analysis of risk factors from a national registry. *Br J Surg* 108(7):851–857. <https://doi.org/10.1093/bjs/znab015>
  139. Materazzi G, Ambrosini CE, Lorenzo Fregoli L, De Napoli L, Frustaci G, Matteucci V, Papini P, Bakkar S, Miccoli P (2017) Prevention and management of bleeding in thyroid surgery. *Gland Surg* 6(5):510–515
  140. Harding J, Sebag F, Sierra M et al (2006) Thyroid surgery: post-operative hematoma—prevention and treatment. *Langenbecks Arch Surg* 391:169–173
  141. Bakkar S, Papavramidis TS, Aljarrah Q, Materazzi G, Miccoli P (2020) Energy-based devices in thyroid surgery—an overview. *Gland Surg* 9(Suppl 1):S14–S17
  142. Konturek A, Szypra B, Stopa-Barczyńska M, Barczyński M (2020) Energy-based devices for hemostasis in thyroid surgery. *Gland Surg* 9(Suppl 2):S153–S158
  143. Soh TCF, Ong QJ, Yip HM (2021) Complications of neck drains in thyroidectomies: a systematic review and meta-analysis. *Laryngoscope* 131:690–700. <https://doi.org/10.1002/lary.29077>
  144. Tian J, Li L, Liu P, Wang X (2017) Comparison of drain versus no-drain thyroidectomy: a meta-analysis. *Eur Arch Oto-Rhino-Laryngol* 274:567–577. <https://doi.org/10.1007/s00405-016-4213-0>
  145. Bajwa MS, Tudur-Smith C, Shaw RJ, Schache AG (2017) Fibrin sealants in soft tissue surgery of the head and neck: a systematic review and meta-analysis of randomised controlled trials. *Clin Otolaryngol* 42:1141–1152. <https://doi.org/10.1111/coa.12837>
  146. Docimo G, Tolone S, Conzo G, Ruggiero R, Docimo L (2016) A gelatin-thrombin matrix topical hemostatic agent (FloSeal) in combination with harmonic scalpel is effective in patients undergoing total thyroidectomy: a prospective, multicenter, single-blind, randomized controlled trial. *Surg Innov* 23(1):23–29
  147. Orloff LA, Wiseman SM, Bernet VJ, Fahey III TJ, Shaha AK, Shindo ML, Samuel K, Snyder SK, Brendan C, Stack BC Jr, John B, Sunwoo JB, Wang MB (2018) American thyroid association statement on postoperative hypoparathyroidism: diagnosis, prevention, and management in adults. *Thyroid* 28:7
  148. Edafe O, Antakia R, Laskar N, Uttley L, Balasubramanian SP (2014) Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia. *Br J Surg* 101:307–320
  149. Pata G, Casella C, Mittempergher F, Cirillo L, Salerni B (2010) Loupe magnification reduces postoperative hypocalcemia after total thyroidectomy. *Am Surg* 76:1345–1350
  150. Sheahan P, Mehanna R, Basheeth N, Murphy M (2013) Is systematic identification of all four parathyroid glands necessary during total thyroidectomy? A prospective study. *Laryngoscope* 123:2324–2328
  151. Saibene AM, Rosso C, Felisati G, Pipolo C, De Leo S, Lozza P, Cozzolino MG, De Pasquale L (2022) Can preoperative 25-hydroxyvitamin D levels predict transient hypocalcemia after total thyroidectomy? *Updates Surg.* 74(1):309–316
  152. Barbieri D, Indelicato P, Vinciguerra A, Di Marco F, Formenti AM, Trimarchi M, Bussi M (2020) Autofluorescence and indocyanine green in thyroid surgery: a systematic review and meta-analysis. *Laryngoscope* 131(7):1683–1692
  153. Pastoriccio M, Bernardi S, Bortoli M, de Manzin N, Dobrinja C (2022) Autofluorescence of parathyroid glands during endocrine surgery with minimally invasive technique. *J Endocrinol Investig.* <https://doi.org/10.1007/s40618-022-01774-x>
  154. Di Marco AN, Palazzo FF (2020) Near-infrared autofluorescence in thyroid and parathyroid surgery. *Gland Surg* 9:136–146
  155. Testini M, Rosato L, Avenia N et al (2007) The impact of single parathyroid gland autotransplantation during thyroid surgery on postoperative hypoparathyroidism: a multicenter study. *Transplant Proc* 39:225–230
  156. Barbieri D, Indelicato P, Vinciguerra A et al (2021) Autofluorescence and indocyanine green in thyroid surgery: a systematic review and meta-analysis. *Laryngoscope* 131:1683–1692. <https://doi.org/10.1002/lary.29297>
  157. Lu W, Chen Q, Zhang P et al (2022) Near-infrared autofluorescence imaging in thyroid surgery: a systematic review and meta-analysis. *J Invest Surg* 35:1723–1732. <https://doi.org/10.1080/08941939.2022.2095468>
  158. De Pasquale L, Sartori PV, Vicentini L et al (2015) Necessity of therapy for post-thyroidectomy hypocalcaemia: a multi-centre experience. *Langenbecks Arch Surg* 400:319–324
  159. Raffaelli M, De Crea C, Carrozza C et al (2012) Combining early postoperative parathyroid hormone and serum calcium levels allows for an efficacious selective post-thyroidectomy supplementation treatment. *World J Surg* 36:1307–1313
  160. Singh N, Singh PN, Hershman JM (2000) Effect of calcium carbonate on the absorption of levothyroxine. *JAMA* 283:2822–2825
  161. Docimo G, Tolone S, Pasquali D, Conzo G, D'Alessandro A, Casalino G, Gili S, Bruscianno L, Gubitosi A, Del Genio G, Ruggiero R, Docimo L (2012) Role of pre and post-operative oral calcium and vitamin D supplements in prevention of hypocalcemia after total thyroidectomy. *Il Giornale di Chirurgia* 33(11–12):374–378
  162. Simó R, Nixon IJ, Rovira A, Vander Poorten V, Sanabria A, Zafereo M, Hartl DM, Kowalski LP, Randolph GW, Kamani D, Shaha AR, Shah J, Marie JP, Rinaldo A, Ferlito A (2021) Immediate intraoperative repair of the recurrent laryngeal nerve in thyroid surgery. *Laryngoscope* 131(6):1429–1435
  163. Tian H, Pan J, Chen L, Wu Y (2022) A narrative review of current therapies in unilateral recurrent laryngeal nerve injury caused by thyroid surgery. *Gland Surg* 11(1):270–278
  164. Ferraro F, Gambardella C, Testa D, Santini I, Marfella R, Fusco P, Lombardi CP, Polistena A, Sanguinetti A, Avenia N, Conzo G (2017) Nasotracheal prolonged safe extubation in acute respiratory failure post-thyroidectomy: an efficacious technique to avoid tracheotomy? A retrospective analysis of a large case series. *Int J Surg* 4:48–54
  165. Karkos PD, Stavrakas M, Koskinas I, Markou K, Triaridis S, Constantinidis J (2021) 5 years of diode laser “5 years of diode laser technique for bilateral vocal fold immobility: a technique that improves airways and is friendly to the voice. *Ear Nose Throat J* 100:83–86
  166. Philteos J, Baran E, Noel CW, Pasternak JD, Higgins KM, Freeman JL et al (2021) Feasibility and safety of outpatient thyroidectomy: a narrative scoping review. *Front Endocrinol (Lausanne)* 12:717427
  167. Reinhart HA, Snyder SK, Stafford SV, Wagner VE, Graham CW, Bortz MD et al (2018) Same day discharge after thyroidectomy is safe and effective. *Surgery* 164(4):887–894
  168. Hahlweg P, Didi S, Kriston L, Härter M, Nestoriuc Y, Scholl I (2017) Process quality of decision-making in multidisciplinary cancer team meetings: a structured observational study. *BMC Cancer* 17(1):772



169. Fenton ME, Wade SA, Pirrili BN, Balogh ZJ, Rowe CW, Bendinelli C (2021) Variability in thyroid cancer multidisciplinary team meeting recommendations is not explained by standard variables: outcomes of a single centre review. *J Clin Med* 10(18):4150
170. Pacini F, Fuhrer D, Elisei R, Handkiewicz-Junak D, Leboulleux S, Luster M et al (2022) 2022 ETA consensus statement: what are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer? *Eur Thyroid J*. 11(1):210046
171. Tuttle RM, Alzahrani AS (2019) Risk stratification in differentiated thyroid cancer: from detection to final follow-up. *J Clin Endocrinol Metab*. 104:4087–4100
172. Mehra S, Tuttle RM, Milas M, Orloff L, Bergman D, Bernet V et al (2015) Database and registry research in thyroid cancer: striving for a new and improved national thyroid cancer database. *Thyroid* 25(2):157–168

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.